var title_f37_49_38672="Disseminated candidiasis kidney";
var content_f37_49_38672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous small abscesses can be seen studding the surface of the kidney in a patient who developed disseminated candidiasis during a chloramphenicol-induced neutropenia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38672=[""].join("\n");
var outline_f37_49_38672=null;
var title_f37_49_38673="RTT develop arrest";
var content_f37_49_38673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome, delvelopmental arrest age one year",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At one year of age, she has loss of eye contact and disinterest in toys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38673=[""].join("\n");
var outline_f37_49_38673=null;
var title_f37_49_38674="Mucous membrane pemphigoid palate";
var content_f37_49_38674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucous membrane pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucosal erosions on the gingiva and palate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38674=[""].join("\n");
var outline_f37_49_38674=null;
var title_f37_49_38675="Carglumic acid: Pediatric drug information";
var content_f37_49_38675=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carglumic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31411?source=see_link\">",
"    see \"Carglumic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/54/34660?source=see_link\">",
"    see \"Carglumic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10107689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbaglu&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F11822312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Metabolic Alkalosis Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urea Cycle Disorder (UCD) Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13450513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute hyperammonemia; adjunct therapy:",
"     </b>",
"     100-250 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations; concomitant ammonia-lowering therapy recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hyperammonemia:",
"     </b>",
"     Usual dose: &lt;100 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F11822320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31411?source=see_link\">",
"      see \"Carglumic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute hyperammonemia:",
"     </b>",
"     100-250 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations; concomitant ammonia-lowering therapy recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic hyperammonemia:",
"     </b>",
"     Usual dose: &lt;100 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be rounded to the nearest 100 mg (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute hyperammonemia; adjunct therapy:",
"     </b>",
"     100-250 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations; concomitant ammonia-lowering therapy recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic hyperammonemia:",
"     </b>",
"     Usual dose: &lt;100 mg/kg/day given in 2 or 4 divided doses; titrate to age-appropriate plasma ammonia concentrations",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10228998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbaglu&reg;: 200 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10228962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11285248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbaglu&reg; is not available through pharmaceutical wholesalers or retail pharmacies, but only through direct shipping from the Accredo specialty pharmacy. Prescribers must contact Accredo Health Group at 888-454-8860 or refer to www.accredo.com to initiate patients on this product.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11822321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer immediately before meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Preparation for administration: Disperse each 200 mg tablet in 2.5 mL of water and swallow; container should be rinsed and contents swallowed immediately; no other food or liquid should be used. Tablets do not dissolve completely and some particles may remain. For partial doses, gently shake the container, draw up the appropriate volume (80 mg/mL) of dispersion into an oral syringe, administer immediately, and discard unused portion. Oral syringe should be refilled with a minimum of 1-2 mL of water and administered immediately. This same dispersion may also be used for nasogastric tube administration, followed by flush with additional water to clear the tube.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11822317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). After opening, do not refrigerate or store above 30&deg;C (86&deg;F); protect from moisture (keep container tightly closed). Discard 1 month after opening.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11822313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency (FDA approved in all ages); maintenance therapy for chronic hyperammonemia due to NAGS deficiency (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F10228971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Hyperhidrosis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dysgeusia, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasopharyngitis, pneumonia, tonsillitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infections, influenza",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11822314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carglumic acid or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13449575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered under the supervision of a physician experienced in metabolic disorders. May cause vomiting, reported in ~25% of patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11822315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute, uncontrolled hyperammonemia may be life-threatening and rapidly cause brain injury or death; carglumic acid in addition to other therapies, including dialysis (preferably hemodialysis), may be necessary until ammonia levels normalize; dietary protein restriction and hypercaloric intake may also be necessary; monitor plasma ammonia concentrations and neurologic status.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10228963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10228964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were reported in some animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. However, due to the potential for irreversible fetal neurologic damage for untreated NAGS deficiency, women with this condition should remain on treatment throughout pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11822322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma ammonia concentrations; physical signs/symptoms of hyperammonemia (eg, lethargy, ataxia, confusion, vomiting, seizures, memory impairment)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11822318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carglumic acid serves as a structural analog to the enzyme N-acetylglutamate (NAG) in patients with N-acetylglutamate synthase (NAGS) deficiency.  NAG is an allosteric activator of the mitochondrial enzyme, carbamoyl phosphate synthetase 1 (CPS 1) responsible for converting ammonia into urea in the first step of the urea cycle within the liver.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13450471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11822319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~2657 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Via intestinal flora to carbon dioxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: Median: 5.6 hours (range: 4.3-9.5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Median: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Feces (60% as unchanged drug); urine (9% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Total: Median: 5.7 L/minute (range: 3-9.7 L/minute)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13450544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/54/34660?source=see_link\">",
"      see \"Carglumic acid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take this medication exactly as prescribed; avoid any OTC medications or herbal products unless approved by prescriber. Should be taken immediately before appropriate meal; do not swallow tablet whole or crush; disperse tablet in water only. May cause vomiting, abdominal pain, headache, or fever. Notify prescriber of any confusion, tiredness, memory impairment, or ataxia. Store unopened container in refrigerator; after opening, store at room temperature and keep tightly closed to protect from moisture; write date opened on container; discard after 1 month from opening.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17067 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38675=[""].join("\n");
var outline_f37_49_38675=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107689\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822312\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450513\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822320\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228998\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228962\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11285248\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822321\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822317\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822313\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228971\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822314\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13449575\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822315\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298977\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228963\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10228964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822322\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450471\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822319\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13450544\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17067|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/43/31411?source=related_link\">",
"      Carglumic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/54/34660?source=related_link\">",
"      Carglumic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38676="Demeclocycline: Patient drug information";
var content_f37_49_38676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Demeclocycline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=see_link\">",
"     see \"Demeclocycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/5/6229?source=see_link\">",
"     see \"Demeclocycline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low sodium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700970",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child younger than 8 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to demeclocycline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, bismuth (Pepto-Bismol&reg;), calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, or antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused part of this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12358 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38676=[""].join("\n");
var outline_f37_49_38676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019005\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019007\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019006\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019011\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019012\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019014\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019009\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019010\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019015\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019016\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/4/10310?source=related_link\">",
"      Demeclocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/5/6229?source=related_link\">",
"      Demeclocycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38677="Frenuloplasty for ankyloglossia";
var content_f37_49_38677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Frenuloplasty for ankyloglossia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Coronal division of a tethering lingual frenulum with bipolar electrosurgical scissors.",
"    <br>",
"     (B) Division of anterior fibers of the genioglossus muscle to release \"posterior\" ankyloglossia.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38677=[""].join("\n");
var outline_f37_49_38677=null;
var title_f37_49_38678="Pearly penile papules";
var content_f37_49_38678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Pearly penile papules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Small white papules are oriented in a few rows on the corona of the penis.",
"    <br>",
"     (B) Whitish pink cobblestone appearance in a few rows with central dotted or comma-like vessels in each papule. The papules are further surrounded by whitish crescent-shaped rims.",
"     <br>",
"      (C) Prominent structures of hyperplastic papillary dermis and dilatation of vascular spaces. The epidermis shows mild acanthosis with orthokeratosis.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Ozeki M, Saito R, Tanaka M. Dermoscopic features of pearly penile papules. Dermatology 2008; 217:21. Copyright &copy; 2008 S. Karger AG.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38678=[""].join("\n");
var outline_f37_49_38678=null;
var title_f37_49_38679="Colonic diverticular bleeding";
var content_f37_49_38679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colonic diverticular bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     Tonia Young-Fadok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     John H Pemberton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38679/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/49/38679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic diverticular bleeding is the most common cause of overt lower gastrointestinal bleeding in adults. In most cases, the bleeding will stop spontaneously. However, if the bleeding persists, endoscopic, radiologic, or surgical intervention may be required.",
"   </p>",
"   <p>",
"    This topic will review colonic diverticular bleeding. The general approach to lower gastrointestinal bleeding, the causes of lower gastrointestinal bleeding, and the evaluation of obscure gastrointestinal bleeding are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colon carcinoma is the most common source of lower gastrointestinal blood loss, but the bleeding is often occult (ie, no evidence of visible blood loss to the patient or clinician). On the other hand, colonic diverticular bleeding is the most common cause of brisk hematochezia (maroon or bright red blood), accounting for 30 to 50 percent of cases of massive rectal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14101?source=see_link\">",
"     \"Complications of hemodialysis in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with diverticulosis, bleeding will occur in approximately 15 percent and will be massive in a third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/4\">",
"     4",
"    </a>",
"    ]. Interestingly, obesity appears to increase the risk of diverticulitis and colonic diverticular bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77762619\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic angioarchitecture is associated with bleeding colonic diverticula (",
"    <a class=\"graphic graphic_figure graphicRef62942 \" href=\"mobipreview.htm?18/21/18771\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/6\">",
"     6",
"    </a>",
"    ]. As a diverticulum herniates, the penetrating vessel responsible for the wall weakness at the point of herniation becomes draped over the dome of the diverticulum, separated from the bowel lumen only by mucosa (",
"    <a class=\"graphic graphic_picture graphicRef52254 \" href=\"mobipreview.htm?18/51/19252\">",
"     picture 1",
"    </a>",
"    ). Over time, the vasa recta is exposed to recurrent injury along its luminal aspect, leading to eccentric intimal thickening and thinning of the media. These changes may result in segmental weakness of the artery, predisposing to rupture into the lumen. It is rare for bleeding to coexist with diverticulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36854?source=see_link\">",
"     \"Epidemiology and pathophysiology of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike diverticulitis, which occurs primarily in the left colon, the right colon is the source of colonic diverticular bleeding in 50 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]. This reflects a marked increase in propensity for right-sided diverticula to bleed since, in western countries, only 25 percent of diverticula are right-sided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/9\">",
"     9",
"    </a>",
"    ]. A possible explanation for this is that right-sided diverticula have wider necks and domes, exposing a greater length of vasa recta to injury. Another contributing factor may be the thinner wall of the right colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160051512\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding stops spontaneously in 75 percent of patients overall and in 99 percent of patients who are transfused less than four units per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/10\">",
"     10",
"    </a>",
"    ]. However, patients who have had an episode of diverticular bleeding have an appreciable risk of rebleeding (14 to 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. After a second bleeding episode, the risk of further hemorrhage is 21 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/10\">",
"     10",
"    </a>",
"    ]. Surgery should be considered for patients who have had multiple episodes of diverticular bleeding and are good surgical candidates. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Surgical intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because many patients with colonic diverticular bleeding are elderly and have comorbid conditions, morbidity and mortality rates from colonic diverticular bleeding together are approximately 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with colonic diverticular bleeding typically present with painless hematochezia that is self-limited. However, in some patients, massive, persistent hematochezia is seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77763637\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painless hematochezia is the typical presentation of a diverticular bleed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/12\">",
"     12",
"    </a>",
"    ]. Most patients who bleed have minor bleeding that is self-limited, and 50 percent have had a previous episode of hematochezia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood originating from the left colon tends to be bright red in color, whereas bleeding from the right side of the colon usually appears dark or maroon-colored and may be mixed with stool. Rarely, melena may be seen in patients with bleeding originating from the right side of the colon.",
"   </p>",
"   <p>",
"    Patients typically have few abdominal symptoms, which is a reflection of the noninflammatory pathogenesis of the bleeding. However, blood within the colon acts as a cathartic, and some patients report bloating, cramping, or the urge to defecate. Symptoms and signs of diverticulitis are not present since the two disorders rarely coexist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with bleeding that is severe enough to cause hemodynamic instability may report syncope, light headedness, or postural dizziness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77763644\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On examination, patients may be normotensive if the bleeding has stopped. However, if the bleeding is severe and ongoing, patients may be tachycardic and hypotensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/12\">",
"     12",
"    </a>",
"    ]. Poor skin turgor, dry skin, oliguria, and altered level of consciousness are late signs of severe bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abdominal examination is typically normal, though some patients may have tenderness to palpation. Blood is usually seen on rectal examination and may be bright red, dark, or rarely, melenic. Nasogastric lavage may be performed to exclude an upper gastrointestinal source of bleeding. In patients with colonic diverticular bleeding, the nasogastric lavage will be negative for blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H5079470#H5079470\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Nasogastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77763651\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial hemoglobin in patients with overt gastrointestinal bleeding will often be at the patient's baseline because the patient is losing whole blood. With time (typically after 24 hours or more), the hemoglobin will decline as the blood is diluted by the influx of extravascular fluid into the vascular space and by fluid administered during resuscitation. It should be kept in mind that overhydration can lead to a falsely low hemoglobin value.",
"   </p>",
"   <p>",
"    Patients with acute bleeding should have normocytic red blood cells. Microcytic red blood cells or iron deficiency anemia suggest chronic bleeding. Unlike in patients with upper gastrointestinal bleeding, the blood urea nitrogen (BUN)-to-creatinine or urea-to-creatinine ratio is not elevated in patients with colonic diverticular bleeding. (See",
"    <a class=\"local\" href=\"#H77762567\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77762559\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of colonic diverticular bleeding may be made with a colonoscopy or radiographic imaging. Once initial resuscitation is complete and an upper gastrointestinal source for the bleeding has been excluded, the test of choice is a colonoscopy (",
"    <a class=\"graphic graphic_algorithm graphicRef60651 \" href=\"mobipreview.htm?30/47/31487\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74147 \" href=\"mobipreview.htm?6/27/6588\">",
"     table 1",
"    </a>",
"    ). Colonoscopy can be used to localize the site of bleeding and provide endoscopic therapy. If colonoscopy fails to reveal a source, nuclear scintigraphy (tagged red blood cell scan) followed by angiography may be able to localize the bleeding site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the diagnostic evaluation of a patient with suspected lower gastrointestinal bleeding is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77762567\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of brisk hematochezia is broad and includes massive upper gastrointestinal bleeding, colon cancer, inflammatory bowel disease, ulcers, angiodysplasia, and severe hemorrhoidal bleeding (",
"    <a class=\"graphic graphic_table graphicRef58308 \" href=\"mobipreview.htm?12/8/12427\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings that suggest an upper gastrointestinal source include hemodynamic instability, melena, or an elevated blood urea nitrogen (BUN)-to-creatinine or urea-to-creatinine ratio (&gt;20:1 or &gt;100:1, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The higher the ratio, the more likely the bleeding is from an upper gastrointestinal source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/14\">",
"     14",
"    </a>",
"    ]. Nasogastric lavage may reveal blood, but a negative lavage does not rule out an upper gastrointestinal bleed. Patients with findings that suggest a possible upper gastrointestinal bleed (even if a lower gastrointestinal bleed is still more likely) should undergo upper endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of lower gastrointestinal bleeding typically can be differentiated from colonic diverticular bleeding based on colonoscopic findings. However, colonic diverticula are common and thus may be seen in patients whose bleeding is from other sources. In a patient with multiple possible bleeding sources, it may not be possible to definitively identify the source if active bleeding is not visualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36854?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathophysiology of colonic diverticular disease\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Massive hemorrhoidal bleeding can be detected with anoscopy. However, massive bleeding from hemorrhoids is rare, so unless significant active bleeding is seen coming from the hemorrhoids, brisk hematochezia should not be ascribed hemorrhoids until other causes have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of colonic diverticular bleeding includes resuscitation and, if the bleeding does not stop spontaneously, treatment of the bleeding site (",
"    <a class=\"graphic graphic_algorithm graphicRef60651 \" href=\"mobipreview.htm?30/47/31487\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77763989\">",
"    <span class=\"h2\">",
"     Resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation is initiated when the patient arrives at the hospital and should not be delayed pending a diagnostic workup. Resuscitation includes obtaining adequate intravenous access (eg, two large caliber peripheral catheters), assessing the patient's need for fluids and blood products, and correcting coagulopathies. Patients who are high risk for complications or who are hemodynamically unstable should be managed in an intensive care unit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77763996\">",
"    <span class=\"h2\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If active bleeding or a visible vessel (similar to stigmata of ulcer hemorrhage) can be localized to a particular diverticulum during colonoscopy, endoscopic therapy can be attempted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. However, it may be difficult to identify the specific diverticulum responsible for bleeding since diverticula often are numerous and bleeding may be intermittent. In addition, while the results of endoscopic therapy are good in the hands of endoscopists who are part of a dedicated gastrointestinal bleeding team [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1\">",
"     1",
"    </a>",
"    ], whether the results are as good when performed by endoscopists who are not part of a dedicated bleeding team is unclear.",
"   </p>",
"   <p>",
"    The efficacy of endoscopic therapy in the hands of an endoscopic team that specializes in gastrointestinal bleeding was demonstrated in a study that included 48 patients with severe hematochezia and diverticulosis who underwent colonoscopy with endoscopic therapy if a bleeding source was identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definite colonic diverticular bleeding source (defined by active bleeding from a diverticulum, a nonbleeding visible vessel, or an adherent clot) was identified in 10 patients (21 percent), all of whom were successfully treated with endoscopic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In patients with active bleeding, treatment included four-quadrant submucosal injection of epinephrine (1 to 2 mL aliquots, dilution 1:20,000) or endoscopic tamponade. In cases of a visualized non-bleeding diverticular vessel, the vessel was treated with bipolar coagulation at a setting of 10 to 15 Watts of power with moderate appositional pressure directly on the vessel using one-second pulses until good coagulation and flattening of the vessel were achieved (",
"      <a class=\"graphic graphic_picture graphicRef58198 \" href=\"mobipreview.htm?39/23/40319\">",
"       picture 2",
"      </a>",
"      ). Nonbleeding adherent clots were injected with epinephrine and shaved down to 3 to 4 mm above the attachment with a polypectomy snare (without coagulation). The underlying stigmata (usually visible vessels) were then coagulated with a bipolar probe.",
"      <br/>",
"      <br/>",
"      In the group that underwent endoscopic treatment, there were no episodes of recurrent bleeding after a median follow-up of 30 months, and no patient required emergency surgery. In a separate group of 17 patients with definite diverticular bleeding who did not receive endoscopic therapy, persistent bleeding after colonoscopy occurred in nine (53 percent). Six of the patients with persistent bleeding underwent surgery, and two suffered complications following surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other endoscopic approaches have been described, including banding the diverticula and using endoscopic hemoclips to control bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One group performed an ex-vivo study on surgical specimens and described successfully \"everting\" and banding 11 diverticula in five of nine specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/23\">",
"       23",
"      </a>",
"      ]. While the authors describe having \"everted\" the diverticula, \"inversion\" would be a more accurate description. Examination of the specimens showed no evidence of muscularis propria or serosal involvement.",
"     </li>",
"     <li>",
"      In a subsequent in vivo study, four patients were successfully banded. The safety of band ligation in the right colon was questioned in another report in which banding of ex-vivo colonic specimens showed gross serosal entrapment, raising concerns for possible subsequent ischemic perforation at that site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 29 patients with 31 diverticula with stigmata or recent hemorrhage (17 of which were in the right colon), 27 diverticula were successfully banded with no complications during a mean follow-up of 11 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/21\">",
"       21",
"      </a>",
"      ]. Diverticular \"eversion\" was noted in 25. Rebleeding occurred in three patients, two of whom were successfully treated with repeat banding or conservative therapy, though one patient required hemicolectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These early experiences with diverticular banding require additional study, preferably in randomized trials, before widespread adoption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is an alternative to colonoscopy for treatment in cases where the bleeding site cannot be identified with colonoscopy, or if a bleeding site is identified but attempts to stop the bleeding endoscopically are unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/24\">",
"     24",
"    </a>",
"    ]. Angiography can detect bleeding rates greater than 0.5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    but must be performed during active bleeding (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52754 \" href=\"mobipreview.htm?38/41/39583\">",
"     image 1",
"    </a>",
"    ). Typically, a tagged red blood cell scan is performed prior to angiography to aid with identification of the bleeding site; alternatively, if a site is identified during colonoscopy, a hemoclip can be placed near the bleeding site to help guide the radiologist. Angiography is 100 percent specific, but sensitivity varies with the pattern of bleeding, ranging in one series from 47 percent with acute bleeding to 30 percent with recurrent hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the site of bleeding is identified, angiographic therapy can be delivered. Angiographic therapies include the infusion of vasoconstricting medications or the delivery of agents to mechanically occlude the vascular supply of the bleeding lesion (embolization). While angiographic therapy achieves hemostasis in up to 95 percent of patients in whom it is technically feasible, rebleeding is a common problem, occurring in up to 56 percent of patients. However, in these patients, angiographic therapy may permit semielective rather than emergent surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link&amp;anchor=H9#H9\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The techniques used for angiographic control of gastrointestinal bleeding are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link&amp;anchor=H331951#H331951\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\", section on 'Angiographic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the bleeding does not stop spontaneously and cannot be controlled with endoscopic or angiographic therapy, surgery is typically required. In addition, instability despite aggressive resuscitation is another indication for surgery and is required in 18 to 25 percent of patients who need blood transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. Finally, surgery should be considered for patients who are good surgical candidates and have recurrent episodes of bleeding. (See",
"    <a class=\"local\" href=\"#H160051512\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Segmental colectomy is performed when the source of bleeding can be localized with colonoscopy or angiography and is associated with a rebleeding rate of 0 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2,10,27\">",
"     2,10,27",
"    </a>",
"    ]. Generally, tagged red blood cell scans are not considered to be accurate enough for localizing a bleeding site and should not be relied on to direct a segmental resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Radionuclide imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A segmental resection that removes the bleeding site is adequate in patients with extensive diverticular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2\">",
"     2",
"    </a>",
"    ]. There is no need to remove all the diverticula. Preoperative localization of the site of bleeding and use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    as a temporizing measure have reduced the operative morbidity from segmental colectomy compared with subtotal colectomy. In one study, the morbidity rate was 8.6 percent for those who had preoperative localization and segmental colectomy, compared with 37 percent for those who underwent emergency subtotal colectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2\">",
"     2",
"    </a>",
"    ]. If the source of bleeding cannot be identified prior to surgery, exploratory laparotomy may identify a source and may be aided by intraoperative colonoscopy. As an example, in a study that included nine patients who underwent exploratory laparotomy, a bleeding source was identified in seven (78 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subtotal colectomy is reserved for patients who continue to bleed without a documented site of bleeding (including those with positive nuclear scintigraphy but negative angiography). It is associated with high morbidity and mortality rates (37 and 11 to 33 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2,10,29\">",
"     2,10,29",
"    </a>",
"    ]. However, the rebleeding rate is virtually nil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blind segmental resection is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    . This procedure is associated with a high rebleeding rate (approximately 40 percent) leading to morbidity and mortality rates that may be as high as 83 and 57 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38679/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/6/1122?source=see_link\">",
"       \"Patient information: Diverticulitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=see_link\">",
"       \"Patient information: Bloody stools (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=see_link\">",
"       \"Patient information: Diverticular disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=see_link\">",
"       \"Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4424668\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonic diverticular bleeding is the most common cause of brisk hematochezia (maroon or bright red blood). It occurs in approximately 15 percent of patients with diverticulosis, and is massive in approximately a third. The right colon is the source of colonic diverticular bleeding in 50 to 90 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding stops spontaneously in 75 percent of patients, but the risk of rebleeding is high (up to 50 percent after two episodes). Since many patients with colonic diverticular bleeding are elderly and have comorbid conditions, morbidity and mortality rates from colonic diverticular bleeding together are approximately 10 to 20 percent. (See",
"      <a class=\"local\" href=\"#H160051512\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Painless hematochezia is the typical presentation of a diverticular bleed, though some patients report bloating, cramping, or the urge to defecate. (See",
"      <a class=\"local\" href=\"#H77763637\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On examination, patients may be normotensive if the bleeding has stopped. However, if the bleeding is severe and ongoing, patients may be tachycardic and hypotensive. Poor skin turgor, dry skin, oliguria, and altered level of consciousness are late signs of severe bleeding. (See",
"      <a class=\"local\" href=\"#H77763644\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial hemoglobin in patients with overt gastrointestinal bleeding will often be at the patient's baseline because the patient is losing whole blood. With time (typically after 24 hours or more), the hemoglobin will decline as the blood is diluted by the influx of extravascular fluid into the vascular space and by fluid administered during resuscitation. (See",
"      <a class=\"local\" href=\"#H77763651\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of colonic diverticular bleeding may be made with a colonoscopy or radiographic imaging. Once initial resuscitation is complete and an upper gastrointestinal source for the bleeding has been excluded, the test of choice is a colonoscopy (",
"      <a class=\"graphic graphic_algorithm graphicRef60651 \" href=\"mobipreview.htm?30/47/31487\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74147 \" href=\"mobipreview.htm?6/27/6588\">",
"       table 1",
"      </a>",
"      ). Colonoscopy can be used to localize the site of bleeding and provide endoscopic therapy. If colonoscopy fails to reveal a source, nuclear scintigraphy (tagged red blood cell scan) followed by angiography may be able to localize the bleeding site. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of colonic diverticular bleeding includes resuscitation and, if the bleeding does not stop spontaneously, treatment of the bleeding site (",
"      <a class=\"graphic graphic_algorithm graphicRef60651 \" href=\"mobipreview.htm?30/47/31487\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77763989\">",
"       'Resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If active bleeding or a visible vessel (similar to stigmata of ulcer hemorrhage) can be localized to a particular diverticulum during colonoscopy, endoscopic therapy can be attempted. (See",
"      <a class=\"local\" href=\"#H77763996\">",
"       'Endoscopic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiography is an alternative to colonoscopy for treatment in cases where the bleeding site cannot be identified with colonoscopy or if a bleeding site is identified but attempts to stop the bleeding endoscopically are unsuccessful. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the bleeding cannot be controlled with endoscopic or angiographic therapy, or if there is persistent instability despite aggressive resuscitation, surgery is typically required. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surgical intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/1\">",
"      Gostout CJ, Wang KK, Ahlquist DA, et al. Acute gastrointestinal bleeding. Experience of a specialized management team. J Clin Gastroenterol 1992; 14:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/2\">",
"      Browder W, Cerise EJ, Litwin MS. Impact of emergency angiography in massive lower gastrointestinal bleeding. Ann Surg 1986; 204:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/3\">",
"      Gayer C, Chino A, Lucas C, et al. Acute lower gastrointestinal bleeding in 1,112 patients admitted to an urban emergency medical center. Surgery 2009; 146:600.",
"     </a>",
"    </li>",
"    <li>",
"     Imbembo AL, Bailey RW. Diverticular disease of the colon. In: Textbook of Surgery, 14th ed, Sabiston DC Jr (Ed), Churchill Livingstone, 1992. p.910.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/5\">",
"      Strate LL, Liu YL, Aldoori WH, et al. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology 2009; 136:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/6\">",
"      Meyers MA, Alonso DR, Gray GF, Baer JW. Pathogenesis of bleeding colonic diverticulosis. Gastroenterology 1976; 71:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/7\">",
"      Casarella WJ, Kanter IE, Seaman WB. Right-sided colonic diverticula as a cause of acute rectal hemorrhage. N Engl J Med 1972; 286:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/8\">",
"      Wong SK, Ho YH, Leong AP, Seow-Choen F. Clinical behavior of complicated right-sided and left-sided diverticulosis. Dis Colon Rectum 1997; 40:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/9\">",
"      Rege RV, Nahrwold DL. Diverticular disease. Curr Probl Surg 1989; 26:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/10\">",
"      McGuire HH Jr. Bleeding colonic diverticula. A reappraisal of natural history and management. Ann Surg 1994; 220:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/11\">",
"      Ud&eacute;n P, Jiborn H, Jonsson K. Influence of selective mesenteric arteriography on the outcome of emergency surgery for massive, lower gastrointestinal hemorrhage. A 15-year experience. Dis Colon Rectum 1986; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/12\">",
"      Wilkins T, Baird C, Pearson AN, Schade RR. Diverticular bleeding. Am Fam Physician 2009; 80:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/13\">",
"      Meyers MA, Volberg F, Katzen B, et al. The angioarchitecture of colonic diverticula. Significance in bleeding diverticulosis. Radiology 1973; 108:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/14\">",
"      Richards RJ, Donica MB, Grayer D. Can the blood urea nitrogen/creatinine ratio distinguish upper from lower gastrointestinal bleeding? J Clin Gastroenterol 1990; 12:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/15\">",
"      Mortensen PB, N&oslash;hr M, M&oslash;ller-Petersen JF, Balslev I. The diagnostic value of serum urea/creatinine ratio in distinguishing between upper and lower gastrointestinal bleeding. A prospective study. Dan Med Bull 1994; 41:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/16\">",
"      Kim YI, Marcon NE. Injection therapy for colonic diverticular bleeding. A case study. J Clin Gastroenterol 1993; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/17\">",
"      Savides TJ, Jensen DM. Colonoscopic hemostasis for recurrent diverticular hemorrhage associated with a visible vessel: a report of three cases. Gastrointest Endosc 1994; 40:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/18\">",
"      Jensen DM, Machicado GA, Jutabha R, Kovacs TO. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 2000; 342:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/19\">",
"      Foutch PG, Zimmerman K. Diverticular bleeding and the pigmented protuberance (sentinel clot): clinical implications, histopathological correlation, and results of endoscopic intervention. Am J Gastroenterol 1996; 91:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/20\">",
"      Barker KB, Arnold HL, Fillman EP, et al. Safety of band ligator use in the small bowel and the colon. Gastrointest Endosc 2005; 62:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/21\">",
"      Ishii N, Setoyama T, Deshpande GA, et al. Endoscopic band ligation for colonic diverticular hemorrhage. Gastrointest Endosc 2012; 75:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/22\">",
"      Simpson PW, Nguyen MH, Lim JK, Soetikno RM. Use of endoclips in the treatment of massive colonic diverticular bleeding. Gastrointest Endosc 2004; 59:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/23\">",
"      Farrell JJ, Graeme-Cook F, Kelsey PB. Treatment of bleeding colonic diverticula by endoscopic band ligation: an in-vivo and ex-vivo pilot study. Endoscopy 2003; 35:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/24\">",
"      Zuccaro G Jr. Management of the adult patient with acute lower gastrointestinal bleeding. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 1998; 93:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/25\">",
"      Fiorito JJ, Brandt LJ, Kozicky O, et al. The diagnostic yield of superior mesenteric angiography: correlation with the pattern of gastrointestinal bleeding. Am J Gastroenterol 1989; 84:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/26\">",
"      Bokhari M, Vernava AM, Ure T, Longo WE. Diverticular hemorrhage in the elderly--is it well tolerated? Dis Colon Rectum 1996; 39:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/27\">",
"      Parkes BM, Obeid FN, Sorensen VJ, et al. The management of massive lower gastrointestinal bleeding. Am Surg 1993; 59:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/28\">",
"      Wagner HE, Stain SC, Gilg M, Gertsch P. Systematic assessment of massive bleeding of the lower part of the gastrointestinal tract. Surg Gynecol Obstet 1992; 175:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38679/abstract/29\">",
"      Setya V, Singer JA, Minken SL. Subtotal colectomy as a last resort for unrelenting, unlocalized, lower gastrointestinal hemorrhage: experience with 12 cases. Am Surg 1992; 58:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2641 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38679=[""].join("\n");
var outline_f37_49_38679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4424668\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77762619\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H160051512\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77763637\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77763644\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77763651\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77762559\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77762567\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77763989\">",
"      Resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77763996\">",
"      Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4424668\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2641|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?30/47/31487\" title=\"algorithm 1\">",
"      Approach to lower GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2641|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/41/39583\" title=\"diagnostic image 1\">",
"      Angiodysplasia colon angio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2641|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/21/18771\" title=\"figure 1\">",
"      Location colonic diverticula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2641|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/51/19252\" title=\"picture 1\">",
"      Bleeding diverticulum endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/23/40319\" title=\"picture 2\">",
"      Endoscopic treatment bleeding diverticulum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/27/6588\" title=\"table 1\">",
"      Localization diverticular bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/8/12427\" title=\"table 2\">",
"      Common causes LGI bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14101?source=related_link\">",
"      Complications of hemodialysis in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36854?source=related_link\">",
"      Epidemiology and pathophysiology of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7272?source=related_link\">",
"      Etiology of lower gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/32/17922?source=related_link\">",
"      Patient information: Diverticular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/6/1122?source=related_link\">",
"      Patient information: Diverticulitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38680="Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions";
var content_f37_49_38680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Sandra J Hong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Sachiko T Cochran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38680/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/49/38680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who has experienced an immediate hypersensitivity reaction (IHR) to radiocontrast media (RCM) is at increased risk for a recurrent IHR with the next exposure to RCM. Measures to prevent recurrent reactions to RCM in patients with past IHRs will be discussed in this topic review. The clinical manifestations, diagnosis, and treatment of IHRs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5021569\">",
"    <span class=\"h1\">",
"     CLINICAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient reporting an \"allergy\" to radiocontrast medium (RCM) should be carefully questioned to determine whether the past reaction was consistent with an immediate hypersensitivity reaction (IHR) or another type of reaction. The recommendations described here are only intended for prevention of recurrent IHRs.",
"   </p>",
"   <p>",
"    Immediate hypersensitivity reactions to RCM develop within one hour of administration, and many begin within five minutes. IHRs have signs and symptoms that are similar or identical to those of anaphylaxis, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flushing",
"     </li>",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Urticaria",
"     </li>",
"     <li>",
"      Angioedema",
"     </li>",
"     <li>",
"      Bronchospasm and wheezing",
"     </li>",
"     <li>",
"      Laryngeal edema and stridor",
"     </li>",
"     <li>",
"      Hypotension and rarely shock",
"     </li>",
"     <li>",
"      Loss of consciousness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RCM can also cause delayed reactions, which are defined as reactions beginning from one hour to several days after administration. These may take many different forms, and the full spectrum of RCM reactions is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link&amp;anchor=H2#H2\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Types of reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTATIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent recurrent reactions in patients with previous IHRs predominantly consist of premedication and use of a different contrast agent. In addition, an allergy evaluation may be considered in patients with severe past IHRs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4554899\">",
"    <span class=\"h2\">",
"     Test dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of test doses of RCM is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended in the prediction or prevention of IHRs and should not be considered a substitute for premedication. Severe and fatal reactions to usual doses of RCM have occurred in patients who tolerated test doses of that agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition, fatalities have resulted from the test doses themselves, even amounts as small as 1 to 2 mL (intravenous) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Premedication regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several premedication regimens have demonstrated efficacy in preventing recurrent IHRs in observational series of patients with previous IHRs, although the optimal approach has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. One widely-used approach combines glucocorticoids and H1 antihistamines with the use of a",
"    <strong>",
"     nonionic low osmolal contrast material",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Categories of agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest the following premedication regimen, with administration beginning 13 hours prior to the procedure (",
"    <a class=\"graphic graphic_table graphicRef59096 \" href=\"mobipreview.htm?4/47/4860\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , given orally 13 hours, 7 hours, and 1 hour before (in adults, 50 mg per dose; in children, 0.5 to 0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, up to 50 mg per dose). If oral administration is not feasible,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      may be administered intravenously at the same time intervals (in adults, 40 mg; in children, 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to a maximum of 40 mg per dose).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      , orally or parenterally given 1 hour before (in adults, 50 mg; in children, 1.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      , up to 50 mg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An observational study examined the efficacy of this premedication regimen in 657 procedures performed in &gt;500 patients with previous IHRs and found that premedication using",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"      prednisone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"      diphenhydramine",
"     </a>",
"    </span>",
"    reduced the rate of breakthrough reactions from a historical level of 17 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5-10\">",
"     5-10",
"    </a>",
"    ], down to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5\">",
"     5",
"    </a>",
"    ]. Premedication was effective regardless of the severity of the initial reaction, although it is likely that the most severe reactors were not entered into this protocol. Of note, this study was performed at a time when hyperosmolal contrast agents, which are associated with higher rates of IHRs, were more commonly used, so the rates of recurrent reactions with modern agents may be even lower.",
"   </p>",
"   <p>",
"    The administration of two doses of glucocorticoids 12 and 2 hours before the procedure was more effective than just one dose 2 hours before, which is consistent with the pharmacology of glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ephedrine was also given in early reports, but it is uncommonly used now, due to multiple contraindications and weak evidence that it reduces reactivity substantially beyond the two drug regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of adding H2 antihistamines to regimens of H1 antihistamines and glucocorticoids is not established, and the authors do not routinely administer H2 antihistamines for premedication. One report found that the combination of H1- and H2-receptor antagonists was more effective in preventing adverse reactions to RCM than either H1 antihistamines alone or glucocorticoids alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/10\">",
"     10",
"    </a>",
"    ]. However, two other reports found that the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    to regimens containing H1 antihistamines and glucocorticoids did not reduce the number of subsequent adverse reactions further [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Use of a different radiocontrast agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid a recurrent IHR, an expert committee has suggested that the patient should never again receive the same specific agent that caused the reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/13\">",
"     13",
"    </a>",
"    ]. The utility of this has not been prospectively confirmed. Despite this, we would suggest use of a structurally unrelated radiocontrast agent until more data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Categories of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various types of RCM are most commonly categorized by osmolality (",
"    <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"     table 2",
"    </a>",
"    ). High osmolal contrast material (HOCM) agents have osmolalities &ge;1400",
"    <span class=\"nowrap\">",
"     mosm/kg",
"    </span>",
"    and low osmolal contrast material (LOCM) agents have osmolalities between 500 and 900",
"    <span class=\"nowrap\">",
"     mosm/kg.",
"    </span>",
"    The lowest osmolality agents are iso-osmolal agents, which are isotonic relative to serum (approximately 290",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"   </p>",
"   <p>",
"    Four",
"    categories can be distinguished if the agents are further subdivided based upon the charge of the iodinated molecule and the molecular structure (",
"    <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"     algorithm 1",
"    </a>",
"    ). Most agents belong to just two groups: ionic HOCM agents or nonionic LOCM agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Low or iso-osmolal contrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;LOCM agents cause significantly fewer IHRs compared with HOCM, and nonionic LOCM agents are recommended for any patient with a previous IHR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/6\">",
"     6",
"    </a>",
"    ]. By extension, we would also suggest consideration of an iso-osmolal agent. The incidence of IHRs associated with each type of RCM is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link&amp;anchor=H12#H12\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Incidence of reactions by type of RCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most centers, use of nonionic LOCM agents for all intravascular procedures has become a widespread practice as the cost differential between LOCM and HOCM has decreased, and with the realization that evaluating, observing, and treating even minor reactions has hidden costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/14\">",
"     14",
"    </a>",
"    ]. We therefore suggest the following, based upon the type of contrast agent that caused the patient's previous reaction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who developed IHRs to HOCM agents in the past, either a nonionic LOCM, an iso-osmolal agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      ), or a gadolinium-based agent should be used for future procedures, in combination with premedications.",
"     </li>",
"     <li>",
"      For patients who experienced a hypersensitivity reaction to a nonionic LOCM in the past, we suggest either an iso-osmolal agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      ) or gadolinium-based agent, in combination with premedications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of using iso-osmolal agents in patients with past IHRs to LOCM has not been specifically studied, although some information may be extrapolated from IHR rates in the general population. The rate of IHRs is significantly lower with the use of the iso-osmolal RCM",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     iodixanol",
"    </a>",
"    (Visipaque) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a randomized parallel-group double-blind study, 1411 patients received either ioxaglate (",
"    <strong>",
"     ionic",
"    </strong>",
"    LOCM) or iodixanol (iso-osmolal) for percutaneous transluminal coronary angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/15\">",
"     15",
"    </a>",
"    ]. The rate of IHRs was significantly lower with iodixanol (0.7 versus 2.5 percent). However, the higher cost of this agent has prevented its widespread use in patients at lower risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A direct comparison between a",
"    <strong>",
"     non",
"    </strong>",
"    ionic LOCM and an iso-osmolal agent is needed for a more definitive recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gadolinium-based agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gadolinium-based chelates are an alternative for patients with a range of adverse reactions to iodinated contrast agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Gadolinium-based chelates are widely used in magnetic resonance imaging (MRI). When used with digital subtraction angiography, gadolinium alone or in conjunction with carbon dioxide can be used to produce diagnostic images for angiography and interventional radiologic procedures.",
"   </p>",
"   <p>",
"    IHRs to these agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/0/4097?source=see_link\">",
"     gadoterate meglumine",
"    </a>",
"    , have been reported, even upon first exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. However, the incidence appears to be very low with reported rates varying widely from 1 to 400 per million procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. One study identified the female sex and a previous IHR to iodinated RCM as risk factors for reacting to gadolinium-based agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several series and case reports document successful use of gadolinium chelates for arteriography, discography, or spiral CT in patients with previous IHRs to iodinated RCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/22,23,35-37\">",
"     22,23,35-37",
"    </a>",
"    ]. A retrospective series of 92 patients with previous IHRs to conventional contrast reported that 127 spinal procedures with gadolinium were completed without any adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the reassuring data above, there are rare patients with IHRs to iodinated RCM who also react to gadolinium, despite premedication. A five-year retrospective review of 78,353 gadolinium administrations identified nine reactions in eight patients, which occurred despite premedication with glucocorticoids and antihistamines (using the same regimen described above for prevention of repeat reactions to iodinated contrast) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/39\">",
"     39",
"    </a>",
"    ]. Three of these eight patients had previously reacted to iodinated contrast agents.",
"   </p>",
"   <p>",
"    Case reports and small series suggest that skin testing with gadolinium agents after an IHR may be useful in identifying alternative gadolinium-based agents that will be tolerated for future use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/29,40,41\">",
"     29,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution should be used in administering gadolinium to patients with moderate to advanced renal failure, due to the association with nephrogenic systemic fibrosis. This complication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1582264\">",
"    <span class=\"h1\">",
"     APPROACH FOR EMERGENT PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid pretreatment protocol has been developed for patients with a previous IHR to RCM requiring an emergency procedure (adult doses shown below) (",
"    <a class=\"graphic graphic_table graphicRef59096 \" href=\"mobipreview.htm?4/47/4860\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      , 40 mg IV immediately and every four hours until completion of procedure",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      , 50 mg",
"      <span class=\"nowrap\">",
"       PO/IV/IM,",
"      </span>",
"      one hour before RCM administration",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Use of the lowest osmolal RCM agent available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency therapy for a possible recurrent reaction should also be available.",
"   </p>",
"   <p>",
"    The efficacy of this regimen was evaluated in a cohort of 10 patients with previous IHRs undergoing emergent procedures. The protocol used in this study used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , 200 mg IV, instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/42\">",
"     42",
"    </a>",
"    ]. One patient also received ephedrine; none experienced a repeat reaction. In contrast, previous published emergent pretreatment regimens used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    only and found reaction rates as high as 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4554678\">",
"    <span class=\"h1\">",
"     UTILITY OF ALLERGY EVALUATION FOR PAST SEVERE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine skin testing of all patients with past IHRs is not an effective means of preventing recurrent reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one study, skin testing was performed in 270,991 patients with previous adverse reactions to RCMs, who were about to receive repeat intravascular RCM injections. The predictive value and sensitivity of skin testing was 1.2 and 3.7 percent, for ionic RCM, and 0 and 0 percent for nonionic RCM, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, routine skin testing was not useful in predicting the vast majority of repeat reactions. Despite this general statement, skin testing",
"    <strong>",
"     might",
"    </strong>",
"    be helpful in evaluating patients with severe IHRs in the recent past, who have a need for additional RCM-requiring studies in the near future. The studies that support this statement are reviewed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743551\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an",
"    <span class=\"nowrap\">",
"     allergist/immunologist",
"    </span>",
"    for skin testing to RCM agents should be considered for patients with severe IHRs in the recent past, who have need for additional radiologic studies involving RCM in the near future. Skin testing should be performed by clinicians experienced in the technique and trained in treating anaphylaxis since there is a very small risk of systemic allergic reactions in response to testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Testing should preferably be performed within two to six months of the original reaction, as the incidence of positive skin tests appears to be lower prior to and after this time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743580\">",
"    <span class=\"h2\">",
"     Technique and interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Intradermal",
"    </strong>",
"    testing of various RCM agents",
"    <strong>",
"     has proved useful",
"    </strong>",
"    in identifying allergic patients with a low frequency of false positives and irritant reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In contrast, the epicutaneous or prick method of skin testing, which uses undiluted RCM, is not sufficiently sensitive to detect agents causing immediate reactions, although it is performed prior to intradermal testing to detect the rare, extremely sensitive patient who is at risk for a systemic reaction with intradermal testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, four percent of patients with severe immediate reactions to RCM had positive skin tests to the RCM agent that caused their IHR. This study evaluated 96 patients who had experienced IHRs to iodinated contrast material, by performing intradermal skin with the culprit RCM agent, as well as four commonly used agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/45/36565?source=see_link\">",
"       iopamidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/46/17126?source=see_link\">",
"       iopromide",
"      </a>",
"      , iomeprol, and iopentol [the latter two agents are not available in the United States] at concentrations of 61 to 66",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/45\">",
"       45",
"      </a>",
"      ]. Evaluation took place within one year of the reaction in 71 percent of subjects.",
"      <br/>",
"      <br/>",
"      Four of 96 patients had positive (defined as a wheal greater than 3 mm) intradermal skin tests to one or more agents, and in all four, the agent that caused the previous reaction yielded a positive result. These patients had all experienced significant respiratory, cardiovascular, or gastrointestinal signs and symptoms within 10 minutes of receiving intravenous contrast agents. Basophil activation tests were then performed with the cells of these four patients and produced results that matched the skin test results. Finally, two of the four patients consented to be challenged with a RCM to which skin testing and basophil activation tests were negative, and both tolerated doses of 50 mL. One of these two patients was subsequently given the culprit agent again for a future CT scan, despite the results of the evaluation. Even with premedication, she developed a moderate-grade IHR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter study evaluated 122 patients with past immediate hypersensitivity reactions and found a much higher rate of skin test positivity among patients who were tested within a few months of their reactions. Skin testing was performed with the culprit RCM if known, as well as several other commonly used agents. Positive intradermal skin tests were seen in 26 percent of patients with IHRs, compared to",
"      <span class=\"nowrap\">",
"       0/11",
"      </span>",
"      exposed controls and",
"      <span class=\"nowrap\">",
"       3/71",
"      </span>",
"      unexposed controls. Patients were statistically more likely to have positive skin test results if tested within two to six months of their reactions",
"      <span class=\"nowrap\">",
"       (14/28",
"      </span>",
"      or 50 percent positive), compared with longer or shorter periods of time",
"      <span class=\"nowrap\">",
"       (17/92",
"      </span>",
"      or 18 percent positive) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44\">",
"       44",
"      </a>",
"      ]. Among skin test&ndash;positive patients in whom the culprit RCM was known (28 cases), skin tests to the culprit agent were positive in 86 percent, indicating that sensitivity is relatively high. In the overall group with positive skin tests, 43 percent had experienced the IHR during their first known exposure to RCM, which suggests that patients may become sensitized to RCM through exposure to a different but related substance, similar to observations in patients allergic to muscle relaxants. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link&amp;anchor=H6#H6\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Neuromuscular blocking agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another series of 38 patients with past IHRs found a similarly high rate of positive skin test results to the culprit agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/46\">",
"       46",
"      </a>",
"      ]. The time elapsed between the reaction and skin testing was not reported. In this study, the causative RCMs were known in each case, and skin testing was performed in 27 patients, with positive results in 19 (74 percent). Among those with positive skin tests, five had reacted to their first known exposure to RCM, confirming the findings of the previously mentioned study. Intradermal testing was performed with multiple dilutions, including undiluted RCM. Among the 19 with positive skin tests, 7 patients reacted to the agent that had caused their reaction only at the undiluted strength. In contrast, when patients were then tested with 10 other RCM agents, only",
"      <span class=\"nowrap\">",
"       9/188",
"      </span>",
"      tests to undiluted RCM were positive, indicating that a positive result to undiluted material was probably a true positive. Another finding in this study was that histamine and tryptase elevations (drawn at the time of the reaction) were more likely in patients with life-threatening reactions involving cardiovascular symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal concentration for intradermal skin testing has not been determined. Based upon the studies described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44,46\">",
"     44,46",
"    </a>",
"    ], we would suggest testing with 1:100, 1:10, and undiluted RCM, as positive results to culprit agents were detected at each of these concentrations.",
"   </p>",
"   <p>",
"    It is important to note that the ability of a skin test reagent to elicit a positive skin test does not prove that a reaction is IgE-mediated, but rather demonstrates that the test agent has the ability to cause immediate release of inflammatory mediators from cutaneous mast cells. This information is only clinically meaningful if a positive test reliably distinguishes between patients who react to that agent and those who tolerate it. More accurate estimates of the sensitivity and specificity of skin testing with RCM are limited by the fact that patients are rarely challenged with RCM to which they tested positive, for ethical reasons. In addition, the optimal control patient in such studies would be individuals who recently tolerated RCM (within the past few months based upon the study above), but this patient population can be difficult to recruit. Instead, patients who tolerated RCM years earlier or who are RCM na&iuml;ve are often used as controls.",
"   </p>",
"   <p>",
"    It is not clear if negative skin test results can reliably predict that a patient will tolerate a given RCM. Only a small number of reports provide information about the negative predictive value (NPV) of intradermal skin testing with RCM in patients with past IHRs. In one retrospective study of 29 highly selected patients, the NPV was estimated to be &gt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/47\">",
"     47",
"    </a>",
"    ]. There are also case reports of patients with past IHRs who were skin test negative to other RCMs and subsequently tolerated those agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the role of an allergy evaluation and skin testing with RCM is evolving because several recent studies suggest that intradermal skin testing may be more useful than previously thought in identifying both the culprit agent and safer alternative agents. The authors and editors of this topic suggest that intradermal skin testing be considered in patients with a history of IHR to RCM within the past year and a need for additional radiologic studies requiring RCM in the near future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BREAKTHROUGH REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No intervention eliminates completely the risk of a breakthrough IHR, and reactions do occur despite premedication and use of a different RCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5-7,9,45,51-54\">",
"     5-7,9,45,51-54",
"    </a>",
"    ]. Therefore, the clinician must be prepared to treat immediate reactions even when preventative steps have been taken. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=see_link&amp;anchor=H20#H20\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough reactions are uncommon when the premedication regimen described above is combined with the use of nonionic LOCM agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study of patients with previous IHRs to conventional RCM, pretreatment with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"        prednisone",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"        diphenhydramine",
"       </a>",
"       ,",
"      </span>",
"      combined with the use of a nonionic LOCM agent, reduced the rate of reactions to 0.7 percent (1 reaction in 141 infusions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent study reported on the same approach in a larger group of patients. Patients with past IHRs were given the premedications above plus a LOCM agent, and the rate of breakthrough reactions was 0.13 percent (190 reactions in 140,753 infusions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, only a small number of patients with initial IHRs will experience breakthrough reactions using this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the large study of breakthrough IHRs described previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/51\">",
"     51",
"    </a>",
"    ], symptoms were similar in severity to initial reactions in approximately 80 percent of patients, an observation that had been made in earlier reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/52\">",
"     52",
"    </a>",
"    ]. The severity of the breakthrough reaction was greater in just 8 percent of patients. Thus, IHRs to RCM do not appear to escalate in severity over time in most cases.",
"   </p>",
"   <p>",
"    Among six patients with severe initial reactions who experienced breakthrough reactions, four had severe recurrent reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, patients with severe initial reactions are at risk for severe breakthrough reactions, even when precautions are taken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Possible risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors were associated with recurrent reaction despite premedications and use of a LOCM in the study of breakthrough reactions described previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38680/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior severe allergic reaction to any substance",
"     </li>",
"     <li>",
"      One or more drug allergies",
"     </li>",
"     <li>",
"      Chronic oral glucocorticoid use",
"     </li>",
"     <li>",
"      Allergy to four or more allergens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with past immediate hypersensitivity reactions (IHRs) to radiocontrast media (RCM) are at increased risk for another reaction upon reexposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients who have experienced an IHR to any type [low osmolal (LOCM) or high osmolal (HOCM)] of iodinated RCM in the past receive premedication prior to any future administrations of contrast (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Premedication regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , given as shown in the table (",
"      <a class=\"graphic graphic_table graphicRef59096 \" href=\"mobipreview.htm?4/47/4860\">",
"       table 1",
"      </a>",
"      ) over regimens of just one drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Premedication regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to premedication, we suggest that patients with past IHRs to RCM never again be given the same agent that caused the initial reaction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Use of a different radiocontrast agent'",
"      </a>",
"      above.) The choice of alternative contrast agent may be approached as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who developed IHRs to a HOCM agent in the past, we recommend either a nonionic LOCM, the iso-osmolal agent (approximately 290",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      H",
"      <sub>",
"       2",
"      </sub>",
"      O)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      , or a gadolinium-based agent (",
"      <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who experienced a hypersensitivity reaction to a LOCM in the past, we suggest either an iso-osmolal agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      ) or a gadolinium-based agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of a previous IHR who require an emergency procedure should receive pretreatment with a rapid protocol (",
"      <a class=\"graphic graphic_table graphicRef59096 \" href=\"mobipreview.htm?4/47/4860\">",
"       table 1",
"      </a>",
"      ), and a nonionic LOCM or iso-osmolal agent should be used (",
"      <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"       table 2",
"      </a>",
"      ). We administer premedication with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1582264\">",
"       'Approach for emergent procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence is accumulating that risk of IHRs to RCM can be assessed by intradermal skin testing more often than previously thought. There may be a role for allergy evaluation with appropriate intradermal testing in patients with severe IHRs in the recent past, and current need for additional RCM studies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/1\">",
"      Yamaguchi K, Katayama H, Takashima T, et al. Prediction of severe adverse reactions to ionic and nonionic contrast media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1991; 178:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/2\">",
"      Witten DM, Hirsch FD, Hartman GW. Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states. Am J Roentgenol Radium Ther Nucl Med 1973; 119:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/3\">",
"      Fischer HW, Doust VL. An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography. Radiology 1972; 103:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/4\">",
"      Yamaguchi K, Katayama H, Kozuka T, et al. Pretesting as a predictor of severe adverse reactions to contrast media. Invest Radiol 1990; 25 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/5\">",
"      Greenberger PA, Patterson R, Radin RC. Two pretreatment regimens for high-risk patients receiving radiographic contrast media. J Allergy Clin Immunol 1984; 74:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/6\">",
"      Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991; 87:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/7\">",
"      Marshall GD Jr, Lieberman PL. Comparison of three pretreatment protocols to prevent anaphylactoid reactions to radiocontrast media. Ann Allergy 1991; 67:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/8\">",
"      Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med 1985; 145:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/9\">",
"      Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/10\">",
"      Ring J, Rothenberger KH, Clauss W. Prevention of anaphylactoid reactions after radiographic contrast media infusion by combined histamine H1- and H2-receptor antagonists: results of a prospective controlled trial. Int Arch Allergy Appl Immunol 1985; 78:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/11\">",
"      Greenberger PA, Patterson R. Adverse reactions to radiocontrast media. Prog Cardiovasc Dis 1988; 31:239.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, 5th ed, American College of Radiology, Reston, VA 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/13\">",
"      Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/14\">",
"      Collins MS, Hunt CH, Hartman RP. Use of IV epinephrine for treatment of patients with contrast reactions: lessons learned from a 5-year experience. AJR Am J Roentgenol 2009; 192:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/15\">",
"      Bertrand ME, Esplugas E, Piessens J, Rasch W. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 2000; 101:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/16\">",
"      Fransson SG, Stenport G, Andersson M. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate. Acta Radiol 1996; 37:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/17\">",
"      Henry DA, Evans DB, Robertson J. The safety and cost-effectiveness of low osmolar contrast media. Can economic analysis determine the real worth of a new technology? Med J Aust 1991; 154:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/18\">",
"      Michalson A, Franken EA Jr, Smith W. Cost-effectiveness and safety of selective use of low-osmolality contrast media. Acad Radiol 1994; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/19\">",
"      Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996; 6:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/20\">",
"      Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/21\">",
"      Rieger J, Sitter T, Toepfer M, et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/22\">",
"      Falco FJ, Moran JG. Lumbar discography using gadolinium in patients with iodine contrast allergy followed by postdiscography computed tomography scan. Spine (Phila Pa 1976) 2003; 28:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/23\">",
"      Coche EE, Hammer FD, Goffette PP. Demonstration of pulmonary embolism with gadolinium-enhanced spiral CT. Eur Radiol 2001; 11:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/24\">",
"      Id&eacute;e JM, Corot C. Anaphylactic shock after first exposure to a macrocyclic gadolinium chelate: a few comments. J Allergy Clin Immunol 2008; 122:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/25\">",
"      Beaudouin E, Kanny G, Blanloeil Y, et al. Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 2003; 35:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/26\">",
"      Weiss KL. Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 1990; 8:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/27\">",
"      Rahman SL, Harbinson MT, Mohiaddin R, Pennell DJ. Acute allergic reaction upon first exposure to gadolinium-DTPA: a case report. J Cardiovasc Magn Reson 2005; 7:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/28\">",
"      Meuli RA, Maeder P. Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine. AJR Am J Roentgenol 1996; 166:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/29\">",
"      Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock after first exposure to gadoterate meglumine: two case reports documented by positive allergy assessment. J Allergy Clin Immunol 2008; 121:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/30\">",
"      Simons CW, Benouni S, Gibbon G, Klaustermeyer W. Severe anaphylactoid shock secondary to gadolinium contrast media. Ann Allergy Asthma Immunol 2009; 103:359.",
"     </a>",
"    </li>",
"    <li>",
"     Commitee on Drugs and Contrast Media. Adverse reactions to gadolinium-based contrast media. Manual on contrast media, American College of Radiology, Reston, VA 1998. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/32\">",
"      Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009; 193:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/33\">",
"      Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010; 194:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/34\">",
"      Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196:W138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/35\">",
"      Hammer FD, Goffette PP, Malaise J, Mathurin P. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999; 9:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/36\">",
"      Spinosa DJ, Angle JF, Hartwell GD, et al. Gadolinium-based contrast agents in angiography and interventional radiology. Radiol Clin North Am 2002; 40:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/37\">",
"      Sakamoto S, Eguchi K, Shibukawa M, et al. Cerebral angiography using gadolinium as an alternative contrast medium in a patient with severe allergy to iodinated contrast medium. Hiroshima J Med Sci 2010; 59:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/38\">",
"      Safriel Y, Ali M, Hayt M, Ang R. Gadolinium use in spine procedures for patients with allergy to iodinated contrast--experience of 127 procedures. AJNR Am J Neuroradiol 2006; 27:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/39\">",
"      Dillman JR, Ellis JH, Cohan RH, et al. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol 2008; 190:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/40\">",
"      Galera C, Pur Ozygit L, Cavigioli S, et al. Gadoteridol-induced anaphylaxis - not a class allergy. Allergy 2010; 65:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/41\">",
"      Chiriac AM, Audurier Y, Bousquet PJ, Demoly P. Clinical value of negative skin tests to gadolinium contrast agents. Allergy 2011; 66:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/42\">",
"      Greenberger PA, Halwig JM, Patterson R, Wallemark CB. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol 1986; 77:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/43\">",
"      Schatz M, Patterson R, O'Rourke J, et al. The administration of radiographic contrast media to patients with a history of a previous reaction. J Allergy Clin Immunol 1975; 55:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/44\">",
"      Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009; 64:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/45\">",
"      Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol 2008; 190:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/46\">",
"      Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol 2011; 77:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/47\">",
"      Caimmi S, Benyahia B, Suau D, et al. Clinical value of negative skin tests to iodinated contrast media. Clin Exp Allergy 2010; 40:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/48\">",
"      Valfrey J, Newinger G, Arbogast R, et al. Anaphylactic shock with ioxaglate during coronary angiography: Two cases. Rev Fr Allergol Immunol Clin 2002; 42:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/49\">",
"      Kanny G, Maria Y, Mentre B, Moneret-Vautrin DA. Case report: recurrent anaphylactic shock to radiographic contrast media. Evidence supporting an exceptional IgE-mediated reaction. Allerg Immunol (Paris) 1993; 25:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/50\">",
"      Dewachter P, Mouton-Faivre C, Felden F. Allergy and contrast media. Allergy 2001; 56:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/51\">",
"      Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009; 253:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/52\">",
"      Freed KS, Leder RA, Alexander C, et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol 2001; 176:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/53\">",
"      Madowitz JS, Schweiger MJ. Severe anaphylactoid reaction to radiographic contrast media. Recurrences despites premedication with diphenhydramine and prednisone. JAMA 1979; 241:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38680/abstract/54\">",
"      Worthley DL, Gillis D, Kette F, Smith W. Radiocontrast anaphylaxis with failure of premedication. Intern Med J 2005; 35:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2076 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38680=[""].join("\n");
var outline_f37_49_38680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5021569\">",
"      CLINICAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTATIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4554899\">",
"      Test dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Premedication regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Use of a different radiocontrast agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Categories of agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Low or iso-osmolal contrast agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gadolinium-based agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1582264\">",
"      APPROACH FOR EMERGENT PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4554678\">",
"      UTILITY OF ALLERGY EVALUATION FOR PAST SEVERE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1743551\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1743580\">",
"      Technique and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BREAKTHROUGH REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Possible risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2076|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/56/5006\" title=\"algorithm 1\">",
"      Scheme for classifying RCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/47/4860\" title=\"table 1\">",
"      Pretreatment for patients with prior RCM reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29662\" title=\"table 2\">",
"      IV contrast media",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38681="Clinical manifestations, diagnosis, and treatment of African trypanosomiasis";
var content_f37_49_38681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of African trypanosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Sanjeev Krishna, MA, BMChB, DPhil, FRCP, ScD, FMedSci",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     August Stich, MD, MSc, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38681/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/49/38681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/1\">",
"     1",
"    </a>",
"    ]. There are two forms of the disease: an acute form occurring mainly in East Africa and caused by Trypanosoma brucei rhodesiense, and a more chronic form occurring mainly in West and Central Africa, caused by Trypanosoma brucei gambiense (",
"    <a class=\"graphic graphic_table graphicRef86456 \" href=\"mobipreview.htm?19/3/19515\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/2\">",
"     2",
"    </a>",
"    ]. These two species have identical morphologic appearances and both are transmitted by tsetse flies of the genus Glossina. However, the clinical infections differ in presentation, management, and prognosis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of African trypanosomiasis will be reviewed here. The epidemiology, life cycle, and prevention of African trypanosomiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=see_link\">",
"     \"Epidemiology, pathogenesis, and prevention of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333420\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human African trypanosomiasis (HAT) is characterized by an early stage, known as the hemolymphatic stage, during which trypanosomes circulate in the blood or lymphatics, and a late stage, in which there is involvement of the central nervous system (CNS). Trypanosoma brucei gambiense causes a slowly progressive infection, and an oligosymptomatic phase can last for months or years. In contrast, Trypanosoma brucei rhodesiense presents as a rapidly progressive infection (often with signs of septicemia), can cause early myocarditis and CNS involvement, and is usually detectable within weeks of infection. Both infections are considered fatal without treatment, although rare instances of asymptomatic infection or resolution of T. brucei gambiense without treatment have been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/3\">",
"     3",
"    </a>",
"    ]. Outside endemic areas, clinical features among returning travellers may differ from clinical features among immigrants (",
"    <a class=\"graphic graphic_table graphicRef86652 \" href=\"mobipreview.htm?19/6/19565\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on African trypanosomiasis and human immunodeficiency virus (HIV) infection are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/5\">",
"     5",
"    </a>",
"    ]; some studies suggest a higher speed of clinical progression and a higher rate of side effects during treatment among HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2334707\">",
"    <span class=\"h2\">",
"     Early infection (stage I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early symptoms of HAT infection include intermittent headache, fevers, malaise, and arthralgias. These symptoms may correspond with successive waves of parasitemia and antibody production. Hepatomegaly and particularly splenomegaly may be observed, and generalized lymphadenopathy may also be present. Other nonspecific symptoms may be present including pruritus, rash, weight loss, and facial swelling. Neuroendocrine disturbances leading to amenorrhea in women or impotence in men may also occur. The duration of this phase is approximately three years in T. b. gambiense infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, T. b. rhodesiense presents as an acute illness with poor demarcation between stages and leading to death within months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333427\">",
"    <span class=\"h3\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trypanosomal chancre may be the first sign of HAT infection; it typically appears approximately one week after the bite of an infected tsetse fly. It is a well-circumscribed, rubbery, painful, indurated, red lesion 2 to 5 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef50285 \" href=\"mobipreview.htm?23/21/23902\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86882 \" href=\"mobipreview.htm?36/56/37767\">",
"     picture 2",
"    </a>",
"    ). It is seen more frequently with infection due to T. b. rhodesiense than T. b. gambiense. The chancre can ulcerate and usually resolves spontaneously after several weeks.",
"   </p>",
"   <p>",
"    Six to eight weeks after infection, a transient, erythematous, urticarial, or macular rash may be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/7\">",
"     7",
"    </a>",
"    ]. Lesions may be poorly defined, centrally pale, evanescent, annular, or blotchy erythematous macules on the trunk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333434\">",
"    <span class=\"h3\">",
"     Lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following skin penetration, trypanosomes travel to regional lymphatics, where they proliferate and cause lymphadenitis. In T. b. gambiense infection, lymphadenopathy can develop at any site, but typically occurs in the posterior cervical nodes. Painless enlargement of these soft, mobile nodes is classically referred to as \"Winterbottom's sign.\" They are easily overlooked.",
"   </p>",
"   <p>",
"    In T. b. rhodesiense infection, lymphadenopathy occurs less frequently. When present, lymphadenopathy occurs more frequently in the submandibular, axillary, or inguinal regions than in the cervical regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333441\">",
"    <span class=\"h2\">",
"     Late infection (stage II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late infection refers to involvement of the central nervous system (CNS). The fatality rate is 100 percent if untreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/9\">",
"     9",
"    </a>",
"    ]. Stage II is defined by an elevation in white blood cell count (&gt;5",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    in the cerebrospinal fluid. Activated plasma cells with IgM-containing eosinophilic inclusions, known as morular cells of Mott, may be observed in cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cerebrospinal fluid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following early T. b. gambiense infection, progressive diffuse meningoencephalitis and parenchymal edema of the brain develop, with perivascular and meningeal inflammatory infiltrates, cerebral microhemorrhages, and widespread multifocal white matter demyelination (Stage II). Symptoms include headache, difficulty concentrating, difficulty completing complex operations (2 or 3 stage tasks), personality changes, psychosis, sensory disorders, tremor, and ataxia. Meningismus and focal neurologic signs may occur but are unusual. Alteration of the circadian",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    cycle leading to daytime somnolence frequently develops. Convulsions may occur, especially in children. Deterioration gradually proceeds until the patient is in a stuporous or comatose state. Cachexia, wasting, and malnutrition develop as patients are too drowsy to eat. Patients are also at risk for complications such as aspiration pneumonia and other secondary bacterial infections. Travelers most commonly present with Stage I disease, but may also complain of headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/4\">",
"     4",
"    </a>",
"    ] or subtle behavioral changes.",
"   </p>",
"   <p>",
"    Symptoms of T. b. rhodesiense infection are similar to those of T. b. gambiense infection, but the presentation and progression are typically much more rapid, usually a matter of weeks. T. b. rhodesiense infection causes an acute, severe febrile disease with myocarditis or pancarditis associated with early death. The illness rapidly progresses to involve the CNS over weeks to a few months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333463\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonspecific laboratory findings may be associated with HAT (",
"    <a class=\"graphic graphic_table graphicRef86654 \" href=\"mobipreview.htm?12/16/12557\">",
"     table 3",
"    </a>",
"    ). Anemia is common (present in more than half of patients) and may be due in part to immune-mediated hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/4\">",
"     4",
"    </a>",
"    ] and cytokine-related bone marrow depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/11\">",
"     11",
"    </a>",
"    ]. Leukocytosis and thrombocytopenia may be present, possibly related to splenic sequestration and massive cytokine release. Hypergammaglobulinemia, largely related to raised levels of polyclonal IgM, is also characteristic and can give rise to false-positive results on serological tests for other diseases. Hypoalbuminemia, hypocomplementemia, elevated erythrocyte sedimentation rate, and elevated C-reactive protein are frequently observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2333470\">",
"    <span class=\"h2\">",
"     Infection in travelers and expatriates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection among travelers is usually acquired in game parks in East Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The incubation period may be as short as a few days. Symptoms include fever, headache, and malaise; rash is also common. Progressive neurologic involvement develops in the absence of treatment.",
"   </p>",
"   <p>",
"    Since T.b. gambiense can present years after exposure, a thorough travel history should be obtained in patients who present with chronic neurologic or psychiatric symptoms; the diagnosis can be missed when the index of suspicion is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/14\">",
"     14",
"    </a>",
"    ]. This was illustrated in a case report of an expatriate presenting with symptoms of psychosis; several alternative diagnoses were considered before confirmation of T. brucei gambiense infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appropriate history of exposure should be identifiable given the limited geographic distribution of human African trypanosomiasis (HAT) (",
"    <a class=\"graphic graphic_figure graphicRef86653 \" href=\"mobipreview.htm?39/3/39986\">",
"     figure 1",
"    </a>",
"    ). Diagnosing HAT requires specialized expertise and significant resources such as well-equipped health centers and qualified staff. Such resources are lacking in many endemic areas that are often in rural locales, so many individuals with HAT die before the diagnosis is established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2358528\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of HAT requires the demonstration of the parasite in blood, lymph node aspirate, chancre aspirate, or cerebrospinal fluid (CSF). T. b. rhodesiense and T. b. gambiense have identical morphologic appearances; the likely etiology can usually be determined based upon geographic exposure and chronicity of symptoms.",
"   </p>",
"   <p>",
"    Staging of disease by examination of the CSF is always required whenever the diagnosis of HAT is suspected, even in the absence of neurologic symptoms; CSF findings are needed for planning therapy.",
"   </p>",
"   <p>",
"    Serologic testing is useful for screening in control programs. Patients with positive serologic test results require parasitologic confirmation of infection for definitive diagnosis. Other diagnostic tests including molecular tools and imaging studies are limited to research settings or use in non-endemic regions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=see_link&amp;anchor=H2333238#H2333238\">",
"     \"Epidemiology, pathogenesis, and prevention of African trypanosomiasis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Clinical specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trypanosomes may be visualized in blood smears, lymph node or chancre aspirates, and in CSF. These specimens may also be cultured with liquid culture medium; cultures may be positive in some patients with negative smears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/16\">",
"     16",
"    </a>",
"    ]. Sometimes live, motile trypanosomes can be seen with dark field illumination in buffy coat preparations or blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/17\">",
"     17",
"    </a>",
"    ]. Clinical specimens are potentially infective and must be handled with universal precautions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     Blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trypanosomes may be visualized on thick smears of peripheral blood stained with Giemsa or direct thin smear preparations (",
"    <a class=\"graphic graphic_picture graphicRef85845 \" href=\"mobipreview.htm?22/49/23317\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef86899 \" href=\"mobipreview.htm?0/32/513\">",
"     picture 4",
"    </a>",
"    ). The sensitivity of blood smear varies with the stage of disease and the infecting species. Smears are most likely to be positive in early stages of infection when there are high numbers of circulating T. b. rhodesiense parasites, since this species is associated with higher levels of parasitemia. Repeat smears should be performed on consecutive days if the initial test is negative, since levels of parasitemia fluctuate. Thick smears can detect parasites if there are at least",
"    <span class=\"nowrap\">",
"     5000/mL.",
"    </span>",
"    T. b. gambiense is less frequently diagnosed on blood smear since circulating numbers are often below the limits of detection.",
"   </p>",
"   <p>",
"    Blood concentration techniques such as hematocrit centrifugation increase the sensitivity of microscopy to 50",
"    <span class=\"nowrap\">",
"     parasites/mL,",
"    </span>",
"    but require technical expertise. A quantitative buffy coat (QBC) technique (which uses centrifugation and a fluorescent stain to identify motile trypanosomes) can also be employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/18\">",
"     18",
"    </a>",
"    ]. Another concentration technique involves a mini-anion exchange column (mAECT); blood is filtered through a resin that retains blood cells but allows trypanosomes to pass through; the eluate is then centrifuged and examined by microscopy. Red cell lysis combined with acridine orange staining of parasites visualized on a cheap light-emitting diode (LED) microscope increases sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/19\">",
"     19",
"    </a>",
"    ]. Microscopy combined with buffy coat separation can detect parasitemia to 10",
"    <span class=\"nowrap\">",
"     parasites/mL,",
"    </span>",
"    but is not widely available in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Tissue aspirate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of lymphadenopathy, a lymph node aspirate may demonstrate motile parasites on direct microscopy of wet mounts; trypanosomes may also be seen after fixation and staining with Giemsa. This method is the traditional diagnostic and screening method in T. b. gambiense infection since lymphadenopathy is more common with this species. In the setting of chancre, aspiration of the lesion may demonstrate trypanosomes. Bone marrow aspirates may also demonstrate parasites in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the CSF is mandatory whenever the diagnosis of HAT is suspected, both to confirm the diagnosis and to stage the infection for planning treatment.",
"   </p>",
"   <p>",
"    The earliest CSF abnormality is pleocytosis. A white blood cell count of &ge;5",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    is considered evidence of CNS involvement in the appropriate epidemiologic and clinical circumstances, even though this finding is not specific for trypanosomiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/21\">",
"     21",
"    </a>",
"    ]. Cell counts are usually below 200",
"    <span class=\"nowrap\">",
"     lymphocytes/microL,",
"    </span>",
"    but levels as high as 2000",
"    <span class=\"nowrap\">",
"     lymphocytes/microL",
"    </span>",
"    may be observed. There is often an associated elevation in protein concentration (autochthonous IgM production in the CSF). Elevated intracranial pressure may also develop. An uncommon but characteristic finding in the CSF is the presence of Mott cells; these are large eosinophilic plasma cells containing IgM that have failed to secrete their antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Trypanosomes are generally scanty but may be observed in the CSF, either on direct examination or following concentration via centrifugation.",
"   </p>",
"   <p>",
"    CSF cytokine, chemokine, and inflammatory profiles in patients with both types of sleeping sickness have been examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/23\">",
"     23",
"    </a>",
"    ]. The most discriminatory marker for Stage II disease is CSF neopterin concentration &gt;14.3",
"    <span class=\"nowrap\">",
"     nmol/L,",
"    </span>",
"    which has a high accuracy for T. brucei gambiense infections (sensitivity and specificity 98 and 88 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody testing for T. b. gambiense is available, but is not definitive for diagnosis. Commercial antibody tests for T. b. rhodesiense are not available, and antigen tests are still in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Antibody detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several serologic tests available for the diagnosis of T. b. gambiense. The antibody tests cannot be used for a definitive diagnosis because of variable sensitivity and specificity, but they can help guide management in cases with a suspected diagnosis and are also useful in epidemiologic surveys.",
"   </p>",
"   <p>",
"    The serologic test used most frequently in the field for screening is the CATT (card agglutination test for T. gambiense trypanosomes), which is based upon agglutination of freeze-dried trypanosomes in the presence of a variant-specific antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The sensitivity varies in different geographic areas but is generally 94 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/26\">",
"     26",
"    </a>",
"    ]. Specificity depends in part upon whether whole blood or plasma dilutions are used; cross reactions with antibodies against nonpathogenic animal trypanosomes also reduce the specificity of the test.",
"   </p>",
"   <p>",
"    Individuals found to be CATT positive should undergo lymph node aspiration and blood smear examination. A high CATT titer, taken together with CSF pleocytosis and the absence of other causes of CSF abnormalities, can provide strong presumptive evidence of HAT.",
"   </p>",
"   <p>",
"    Tests to detect anti-trypanosomal antibodies in the CSF have been developed but lack sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/21\">",
"     21",
"    </a>",
"    ]. Increased intrathecal synthesis of IgM has been identified as one of the most sensitive indicators of CNS involvement in HAT. Elevations in neopterin concentrations may provide some additional discrimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/21,23,27,28\">",
"     21,23,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen detection enzyme linked immunosorbent assay (ELISA) techniques for detection of trypanosomal antigens have been developed but are not commercially available and have demonstrated inconsistent results. In one study evaluating performance of an ELISA for the detection of T. b. rhodesiense antigen in serum or CSF, the test was positive in 88 to 97 percent of parasitologically confirmed cases and there was no cross-reactivity with common bacterial, viral, or parasitic diseases prevalent in the areas where the studies were conducted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2358752\">",
"    <span class=\"h3\">",
"     Molecular tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isoenzyme analysis, restriction fragment length polymorphism (RFLP), and animal inoculation have been used for definitive subspecies identification in research settings.",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) has been used to diagnose HAT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/30\">",
"     30",
"    </a>",
"    ], although it is not often available in endemic countries and is still an investigational tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/31\">",
"     31",
"    </a>",
"    ]. Loop-mediated isothermal amplification (LAMP) is simpler technique than PCR for copying DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Nucleic acid amplification strategies have sensitivity and specificity of 99 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel mass spectrometric analytic method using serum has been reported to have a 100 percent sensitivity and 98.6 percent specificity for patients with HAT, although the technology is not appropriate for field use and simplified approaches would need to be developed for use in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on magnetic resonance imaging (MRI) findings of HAT are limited. T2-weighted MRI scans show hyperintense signals in frontal cortical and periventricular white matter, together with involvement of basal ganglia and cerebellum in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/36\">",
"     36",
"    </a>",
"    ]. Another report noted multiple lesions in white and central gray matter and cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/37\">",
"     37",
"    </a>",
"    ]. Resolution of abnormalities may take many months or longer.",
"   </p>",
"   <p>",
"    Patients with neurologic involvement often have abnormal electroencephalograms (EEGs), usually demonstrating slow wave oscillations (delta waves) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/38\">",
"     38",
"    </a>",
"    ]. However this is a nonspecific finding, and EEGs are rarely performed in endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359067\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of late stage HAT includes HIV, tuberculosis, toxoplasmosis, meningitis, lymphoma, and inflammatory CNS diseases including autoimmune disorders. Early T. b. gambiense infection can last for a few years and may be mistaken for a chronic hematological condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"     6",
"    </a>",
"    ]. Infection in travelers may be misdiagnosed as psychiatric illness when past exposure is not recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/15,39\">",
"     15,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatments for T. b. gambiense and T. b. rhodesiense differ, and the regimen for each species depends upon the stage of infection (",
"    <a class=\"graphic graphic_table graphicRef86457 \" href=\"mobipreview.htm?18/9/18588\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients are likely to fail therapy if there is subclinical central nervous system (CNS) involvement and treatment for early stage disease is administered. Thus, as noted above, all patients must undergo cerebrospinal fluid (CSF) evaluation prior to determination of therapy, even in the absence of neurologic symptoms.",
"   </p>",
"   <p>",
"    All treatment regimens involve toxic or expensive drugs that are cumbersome to administer. It is estimated that 3 to 5 percent of patients treated for late stage infection die from treatment side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359284\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment regimens and dosing for different stages of disease are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef86457 \" href=\"mobipreview.htm?18/9/18588\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/40\">",
"     40",
"    </a>",
"    ]. All drugs used for treatment of HAT are toxic, and there is pressing need for an effective safe drug for both stages of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359291\">",
"    <span class=\"h3\">",
"     T. b. gambiense",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of early T. b. gambiense infection consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    ; this agent has been used for several decades.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     Suramin",
"    </a>",
"    is an alternative agent. Pentamidine and suramin have equal efficacy, but pentamidine is better tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pentamidine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4239615\">",
"     'Suramin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The preferred treatment for late T. b. gambiense infection consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    , either alone or in combination with nifurtimox if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. Eflornithine has been confirmed to be safer than melarsoprol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/43,47\">",
"     43,47",
"    </a>",
"    ] and is gradually replacing melarsoprol as first-line treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/46,48\">",
"     46,48",
"    </a>",
"    ], although its use is constrained by logistics and nursing requirements. Efforts to shorten and simplify eflornithine-based therapy have been successful with a randomized trial which demonstrated that nifurtimox-eflornithine combination therapy (NECT) was not inferior to eflornithine monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/49\">",
"     49",
"    </a>",
"    ]. NECT has been added to the World Health Organization (WHO) Essential Medicine List [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/50\">",
"     50",
"    </a>",
"    ], and further clinical studies are underway. (See",
"    <a class=\"local\" href=\"#H4239231\">",
"     'Eflornithine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4239238\">",
"     'Nifurtimox combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Melarsoprol was the only treatment available for late T. b. gambiense infection for more than 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/9\">",
"     9",
"    </a>",
"    ]. Cure rates of 86 percent at two years following therapy have been described, but nearly half of patients were lost to follow up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/51\">",
"     51",
"    </a>",
"    ]. Another study noted that up to 30 percent of patients with T. b. gambiense failed to respond to melarsoprol in certain areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/52\">",
"     52",
"    </a>",
"    ]. A melarsoprol treatment schedule of 10 daily injections has been demonstrated to have similar safety and efficacy as a prolonged discontinuous regimen for treatment of T. b. gambiense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/51,53,54\">",
"     51,53,54",
"    </a>",
"    ]. Arsenic encephalopathy is a common and potentially fatal complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/51\">",
"     51",
"    </a>",
"    ]; corticosteroids can reduce its likelihood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/55\">",
"     55",
"    </a>",
"    ]. Combination therapy with melarsoprol and nifurtimox appears promising; further study is needed. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Melarsoprol'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4239238\">",
"     'Nifurtimox combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following treatment, patients should be monitored for with lumbar puncture every six months for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"     6",
"    </a>",
"    ]. Relapse is present if there is a rise in CSF white count or demonstration of trypanosomes in CSF, blood, or lymph node aspirate. One study noted success with a follow-up duration of one year rather than two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to treatment of relapse is uncertain. Relapse after early T. b. gambiense (treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    ) may be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    or melarsoprol. Relapse after late T. b. gambiense (treated with melarsoprol) may be treated with eflornithine. Relapse after late T. b. gambiense (treated with eflornithine) may be treated with melarsoprol.",
"   </p>",
"   <p>",
"    Examination of CSF at six months post-treatment can be useful for prediction of outcome in some cases; thresholds of &le;5",
"    <span class=\"nowrap\">",
"     leukocytes/mcL",
"    </span>",
"    for cure and &ge;50",
"    <span class=\"nowrap\">",
"     leucocytes/mcL",
"    </span>",
"    for relapse had sensitivity and specificity of 87 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/57\">",
"     57",
"    </a>",
"    ]. Rigorous reporting of treatment outcome is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2359298\">",
"    <span class=\"h3\">",
"     T. b. rhodesiense",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of early T. b. rhodesiense infection consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    . Adverse effects include nephrotoxicity, peripheral neuropathy and bone marrow toxicity; these are usually mild and reversible. Rarely, acute hypersensitivity reactions can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4239615\">",
"     'Suramin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Management of late T. b. rhodesiense infection consists of melarsoprol;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    has no activity. Data on use of melarsoprol for treatment of T. b. rhodesiense infection are limited; more data are available on use of melarsoprol for treatment of T. b. gambiense. A melarsoprol treatment schedule of 10 daily injections has been demonstrated to have similar safety and efficacy as a prolonged discontinuous regimen for treatment of T. b. gambiense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following treatment, patients should be monitored for with lumbar puncture every six months for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"     6",
"    </a>",
"    ]. Relapse is present if there is a rise in CSF white count or demonstration of trypanosomes in CSF, blood, or lymph node aspirate.",
"   </p>",
"   <p>",
"    The optimal approach to treatment of relapse is uncertain. In general, patients with relapse after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    or melarsoprol may be (re)treated with melarsoprol.",
"   </p>",
"   <p>",
"    If treated appropriately, patients presenting late in the course of infection or in coma may recover without neurologic sequelae. Children may have psychomotor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic retardation following treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Agents with trypanosomal activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents with trypanosomal activity are discussed below as well as in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17335?source=see_link\">",
"     \"Antiprotozoal therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pentamidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     Pentamidine",
"    </a>",
"    is an aromatic diamidine compound. Its use is limited to early infection (eg, without CNS involvement) because it has poor CSF penetration. Pentamidine is used largely for T. b. gambiense infections; it is much less effective in T. b. rhodesiense infection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     Pentamidine",
"    </a>",
"    is available as an isethionate salt and must be administered parenterally (intramuscularly or intravenously) for treatment of trypanosomiasis. Intravenous administration is usually preferred if conditions allow since intramuscular injections are painful.",
"   </p>",
"   <p>",
"    Adverse effects occur in more than half of patients treated with parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    . Immediate reactions include nausea, anorexia, dizziness, pruritus, and hypotension. Pentamidine is also associated with hematologic effects (particularly leukopenia and thrombocytopenia) as well as electrolyte abnormalities (including hyperkalemia, hypomagnesemia, and hypocalcemia). Other severe adverse effects include ventricular arrhythmias, pancreatitis, hypo- or hyperglycemia, hepatotoxicity, and acute renal failure. Pentamidine has been associated with Stevens-Johnson syndrome. Seizures and hallucinations have also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4239231\">",
"    <span class=\"h3\">",
"     Eflornithine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    is trypanostatic; it inhibits parasite growth by inhibition of ornithine carboxylase, an enzyme required for cellular proliferation and differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The drug crosses the blood brain barrier and has good CSF penetration. It is used for treatment of late stage infection due to T. b. gambiense; it is not effective against T. b. rhodesiense as this parasite has a much higher turnover rate of the target enzyme. Eflornithine is contraindicated in pregnancy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    is administered intravenously; administration is cumbersome because of large volumes and frequent dosing requirements. Oral administration of eflornithine is impractical because the drug causes osmotic diarrhea, limiting absorption.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    occur in up to 40 percent of patients and include vomiting, abdominal pain, dizziness, arthralgias, hearing loss, seizure, rash, alopecia, and bone marrow toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    has fewer adverse effects than melarsoprol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/43,61\">",
"     43,61",
"    </a>",
"    ]. This was illustrated in a retrospective review of 959 patients with trypanosomiasis treated with melarsoprol or eflornithine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients treated with eflornithine had lower mortality (RR 0.2) and lower rates of encephalopathy compared with patients treated with melarsoprol (11 versus 0.4 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     Eflornithine",
"    </a>",
"    is available from the World Health Organization (WHO).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4239238\">",
"    <span class=\"h3\">",
"     Nifurtimox combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nifurtimox is a synthetic nitrofuran compound with activity against Trypanosoma cruzi, the causative agent of American trypanosomiasis or Chagas disease. Its efficacy in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    or melarsoprol has been evaluated for treatment of late stage T. b. gambiense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/49,62\">",
"     49,62",
"    </a>",
"    ]. Nifurtimox eflornithine combination therapy (NECT) is the treatment of choice for late-stage T. b. gambiense infection. Combination therapy is more effective than monotherapy and facilitates shorter duration of therapy, reduces costs, and reduces likelihood of resistance.",
"   </p>",
"   <p>",
"    To evaluate the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"     eflornithine",
"    </a>",
"    with nifurtimox, 103 adults with late stage T. b. gambiense infection were randomized to receive eflornithine monotherapy (400",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    intravenously every 6 hours for 14 days) or eflornithine (400",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    intravenously every 12 hours for 7 days) plus nifurtimox (15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    orally every 8 hour for 10 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/49\">",
"     49",
"    </a>",
"    ]. Cure rates were similar (94 and 96 percent, respectively), although adverse effects occurred more frequently in the eflornithine monotherapy group that received higher cumulative dose (25 versus 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a cohort study including 564 adults and 120 children with late stage T. b. gambiense infection in the Democratic Republic of the Congo, adverse effects included vomiting, dizziness, headache, and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/63\">",
"     63",
"    </a>",
"    ]. Most adverse effects were mild or moderate, and adverse effects were observed more frequently in adults than in children.",
"   </p>",
"   <p>",
"    To evaluate the efficacy of melarsoprol with nifurtimox, 278 patients with T. b. gambiense were randomly assigned to treatment with melarsoprol monotherapy, nifurtimox monotherapy, or nifurtimox monotherapy followed by melarsoprol-nifurtimox combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/62\">",
"     62",
"    </a>",
"    ]. Although the trial could not be completed due to political instability, relapses were observed in 48 cases and occurred only among those patients who received monotherapy.",
"   </p>",
"   <p>",
"    Adverse effects of nifurtimox include gastrointestinal and cognitive effects, seizures, and allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Melarsoprol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melarsoprol is a trivalent arsenical compound. It is used for the treatment of late stages of T. b. gambiense and T. b. rhodesiense infections involving the CNS. It is the only agent available for the treatment of late stage infection due to T. b. rhodesiense. Melarsoprol is generally administered by slow intravenous infusion. It is estimated that &lt;1 percent penetrates the CNS, but it is such an effective trypanocidal agent that it is useful for late trypanosomal infection nonetheless.",
"   </p>",
"   <p>",
"    Melarsoprol is associated with significant toxicity including vomiting, rash, abdominal pain, hepatotoxicity, peripheral neuropathy, paraplegia, cardiac arrhythmias, and albuminuria. The injection is very irritating and thrombophlebitis may occur; extravasation during intravenous administration should be avoided. Arsenic encephalopathy occurs in up to 10 percent of treated patients and is fatal in about half of those cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/37,64\">",
"     37,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link\">",
"     \"Arsenic exposure and poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of encephalopathy increases with the trypanosomal burden and with a CSF white blood cell count, presumably because it reflects an immune reaction against trypanosomes in the CNS. Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), reduces risk of melarsoprol induced encephalopathy by two-thirds and reduces mortality by 50 percent, and does not affect treatment efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/55,65\">",
"     55,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the treatment regimen consisted of 12 melarsoprol injections over a 30-day period. Subsequently, a treatment schedule of 10 daily injections was demonstrated to have similar safety and efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/51,53,54\">",
"     51,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to melarsoprol therapy has emerged. In one study, up to 30 percent of patients in the Congo and Uganda did not respond to melarsoprol treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/66\">",
"     66",
"    </a>",
"    ]. A fluorescence test for rapid detection of melarsoprol resistance is being developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, melarsoprol is available from the Centers for Disease Control and Prevention (CDC) on a compassionate use protocol. The CDC Drug Service telephone number is (404) 639-3670 or (404) 770-7100.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4239615\">",
"    <span class=\"h3\">",
"     Suramin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     Suramin",
"    </a>",
"    is a polysulfonated naphthylamine derivative of urea. It is used for early infection due to T. b. gambiense or T. b. rhodesiense infection. The drug does not cross the blood brain barrier, and therefore cannot be used in the setting of CNS involvement.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     Suramin",
"    </a>",
"    is dispensed as a sodium salt. It is not absorbed when given orally and is usually administered as a 10 percent solution by slow intravenous infusion. Suramin should not be administered in patients with severe renal or liver disease.",
"   </p>",
"   <p>",
"    An immediate hypersensitivity reaction leading to nausea, vomiting, shock, and loss of consciousness can occur following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    administration. The risk of anaphylaxis is estimated to occur in 1:20,000 patients. Given this risk, a test dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should be given prior to administration of suramin.",
"   </p>",
"   <p>",
"    Other adverse effects include renal impairment, exfoliative dermatitis, and neurologic toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     Suramin",
"    </a>",
"    has also been associated with pancytopenia. Given the potential nephrotoxic effects, a urinalysis should be performed to check for proteinuria prior to each dose. Onchocerciasis coinfection may increase risk for serious adverse events with suramin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38681/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    is available from the CDC on a compassionate use basis. The CDC Drug Service telephone number is (404) 639-3670 or (404) 770-7100.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269791973\">",
"    <span class=\"h3\">",
"     Drugs in the pipeline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs available for treatment of HAT are toxic and difficult to administer; new drugs are urgently needed. There has been relatively little research on new drugs in spite of a huge body of basic science research on HAT. The diamidine derivative DB289 was arrested in development due to a high rate of adverse effects in clinical trials. Flexinidazole is entering phase II clinical trials. Oxaborole could be another promising candidate in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4241093\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites transmitted via the bite of a tsetse fly. There are two forms of HAT: a chronic form occurring mainly in West and Central Africa, caused by Trypanosoma brucei gambiense, and an acute form occurring mainly in East Africa, caused by Trypanosoma brucei rhodesiense. T. b. gambiense generally causes endemic disease with chronic manifestations, while T. b. rhodesiense is an acute epidemic disease (",
"      <a class=\"graphic graphic_table graphicRef86456 \" href=\"mobipreview.htm?19/3/19515\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HAT is characterized by an early stage, known as the hemolymphatic stage, during which trypanosomes circulate in the blood or lymphatics, and a late stage, in which there is involvement of the central nervous system (CNS). T. b. gambiense causes a slowly progressive infection, and the asymptomatic phase can last for months or years. In contrast, T. b. rhodesiense causes a rapidly progressive infection, can cause early myocarditis and CNS involvement, and is often detectable within weeks of infection. Both infections are fatal without treatment. (See",
"      <a class=\"local\" href=\"#H2333420\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis of HAT requires the demonstration of the parasite in blood, lymph node aspirate, chancre aspirate, or cerebrospinal fluid (CSF). T. b. rhodesiense and T. b. gambiense have identical morphologic appearances; the likely etiology can usually be determined based upon geographic exposure and chronicity of symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staging of disease by examination of the CSF is required whenever the diagnosis of HAT is suspected, even in the absence of neurologic symptoms; CSF findings are needed for planning therapy. A white blood cell count of &ge;5",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      is considered evidence of CNS involvement in the appropriate epidemiologic and clinical circumstances, even though this finding is not specific for trypanosomiasis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cerebrospinal fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatments for T. b. gambiense and T. b. rhodesiense differ, and the regimen for each species depends upon the stage of infection. The treatment regimens and dosing for different stages of disease are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef86457 \" href=\"mobipreview.htm?18/9/18588\">",
"       table 4",
"      </a>",
"      ). All drugs used for treatment of HAT are toxic, and there is pressing need for an effective safe drug for both stages of disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of early T. b. gambiense infection, we recommend administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"       pentamidine",
"      </a>",
"      (rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"       suramin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For treatment of late T. b. gambiense infection, we recommend administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37652?source=see_link\">",
"       eflornithine",
"      </a>",
"      , either alone or in combination with nifurtimox if available (rather than melarsoprol) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This approach to treatment is based upon the likelihood of adverse drug effects. Management of early T. b. rhodesiense infection consists of suramin; management of late T. b. rhodesiense infection consists of melarsoprol. There are no alternative agents for treatment of T. b. rhodesiense infection; eflornithine has no sufficient activity against this species. (See",
"      <a class=\"local\" href=\"#H2359284\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment, patients should be monitored for with lumbar puncture every six months for two years. Relapse is present if there is a rise in CSF white count or demonstration of trypanosomes in CSF, blood, or lymph node aspirate. The optimal approach to treatment of relapse is uncertain; this is discussed above. (See",
"      <a class=\"local\" href=\"#H2359291\">",
"       'T. b. gambiense'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2359298\">",
"       'T. b. rhodesiense'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H769240\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/1\">",
"      Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/2\">",
"      Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003; 362:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/3\">",
"      Jamonneau V, Ilboudo H, Kabor&eacute; J, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 2012; 6:e1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/4\">",
"      Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/5\">",
"      P&eacute;pin J, M&eacute;da HA. The epidemiology and control of human African trypanosomiasis. Adv Parasitol 2001; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/6\">",
"      Malvy D, Chappuis F. Sleeping sickness. Clin Microbiol Infect 2011; 17:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/7\">",
"      Uslan DZ, Jacobson KM, Kumar N, et al. A woman with fever and rash after African safari. Clin Infect Dis 2006; 43:609, 661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/8\">",
"      Boatin BA, Wyatt GB, Wurapa FK, Bulsara MK. Use of symptoms and signs for diagnosis of Trypanosoma brucei rhodesiense trypanosomiasis by rural health personnel. Bull World Health Organ 1986; 64:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/9\">",
"      Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 2008; 64:116.",
"     </a>",
"    </li>",
"    <li>",
"     Krishna S, Stich A. Human African Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Infections, 9th ed, Magill AJ, Maguire JH, Ryan ET, Solomon T.  (Eds), Elsevier, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/11\">",
"      W&eacute;ry M, Mulumba PM, Lambert PH, Kazyumba L. Hematologic manifestations, diagnosis, and immunopathology of African trypanosomiasis. Semin Hematol 1982; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/12\">",
"      Jelinek T, Bisoffi Z, Bonazzi L, et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 2002; 8:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/13\">",
"      Migchelsen SJ, B&uuml;scher P, Hoepelman AI, et al. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int J Infect Dis 2011; 15:e517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/14\">",
"      Lejon V, Boelaert M, Jannin J, et al. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003; 3:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/15\">",
"      Sahlas DJ, MacLean JD, Janevski J, Detsky AS. Clinical problem-solving. Out of Africa. N Engl J Med 2002; 347:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/16\">",
"      Truc P, Aerts D, McNamara JJ, et al. Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of gambian trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/17\">",
"      Rosenblatt JE. Laboratory diagnosis of infections due to blood and tissue parasites. Clin Infect Dis 2009; 49:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/18\">",
"      Bailey JW, Smith DH. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/19\">",
"      Bi&eacute;ler S, Matovu E, Mitashi P, et al. Improved detection of Trypanosoma brucei by lysis of red blood cells, concentration and LED fluorescence microscopy. Acta Trop 2012; 121:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/20\">",
"      Lumsden WH, Kimber CD, Dukes P, et al. Field diagnosis of sleeping sickness in the Ivory Coast. I. Comparison of the miniature anion-exchange/centrifugation technique with other protozoological methods. Trans R Soc Trop Med Hyg 1981; 75:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/21\">",
"      Lejon V, B&uuml;scher P. Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health 2005; 10:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/22\">",
"      Bain BJ. Russell bodies and Mott cells. Am J Hematol 2009; 84:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/23\">",
"      Tiberti N, Hainard A, Lejon V, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One 2012; 7:e40909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/24\">",
"      Truc P, Lejon V, Magnus E, et al. Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. Bull World Health Organ 2002; 80:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/25\">",
"      Inojosa WO, Augusto I, Bisoffi Z, et al. Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ 2006; 332:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/26\">",
"      Simarro PP, Ruiz JA, Franco JR, Josenando T. Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Qui&ccedil;ama (Angola). Trop Med Int Health 1999; 4:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/27\">",
"      Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev 2005; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/28\">",
"      Lejon V, Sindic CJ, Van Antwerpen MP, et al. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response. Eur J Neurol 2003; 10:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/29\">",
"      Komba E, Odiit M, Mbulamberi DB, et al. Multicentre evaluation of an antigen-detection ELISA for the diagnosis of Trypanosoma brucei rhodesiense sleeping sickness. Bull World Health Organ 1992; 70:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/30\">",
"      Deborggraeve S, Claes F, Laurent T, et al. Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol 2006; 44:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/31\">",
"      Jamonneau V, Solano P, Garcia A, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in C&ocirc;te d'Ivoire. Trop Med Int Health 2003; 8:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/32\">",
"      Wastling SL, Picozzi K, Kakembo AS, Welburn SC. LAMP for human African trypanosomiasis: a comparative study of detection formats. PLoS Negl Trop Dis 2010; 4:e865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/33\">",
"      Njiru ZK, Traub R, Ouma JO, et al. Detection of Group 1 Trypanosoma brucei gambiense by loop-mediated isothermal amplification. J Clin Microbiol 2011; 49:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/34\">",
"      Mugasa CM, Adams ER, Boer KR, et al. Diagnostic accuracy of molecular amplification tests for human African trypanosomiasis--systematic review. PLoS Negl Trop Dis 2012; 6:e1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/35\">",
"      Papadopoulos MC, Abel PM, Agranoff D, et al. A novel and accurate diagnostic test for human African trypanosomiasis. Lancet 2004; 363:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/36\">",
"      Kager PA, Schipper HG, Stam J, Majoie CB. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature. Am J Trop Med Hyg 2009; 80:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/37\">",
"      Braakman HM, van de Molengraft FJ, Hubert WW, Boerman DH. Lethal African trypanosomiasis in a traveler: MRI and neuropathology. Neurology 2006; 66:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/38\">",
"      Chimelli L, Scaravilli F. Trypanosomiasis. Brain Pathol 1997; 7:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/39\">",
"      B&eacute;dat-Millet AL, Charpentier S, Monge-Strauss MF, Woimant F. [Psychiatric presentation of human African trypanosomiasis: overview of diagnostic pitfalls, interest of difluoromethylornithine treatment and contribution of magnetic resonance imaging]. Rev Neurol (Paris) 2000; 156:505.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections. Medical Lett Drugs Ther; August 2004 www.medletter.com/freedocs/parasitic.pdf (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Medical Letter, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/42\">",
"      Milord F, P&eacute;pin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992; 340:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/43\">",
"      Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/44\">",
"      Chappuis F. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clin Infect Dis 2007; 45:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/45\">",
"      Khonde N, P&eacute;pin J, Niyonsenga T, et al. Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/46\">",
"      Simarro PP, Franco J, Diarra A, et al. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 2012; 139:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/47\">",
"      Balasegaram M, Young H, Chappuis F, et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine M&eacute;decins Sans Fronti&egrave;res programmes. Trans R Soc Trop Med Hyg 2009; 103:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/48\">",
"      Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst Rev 2010; :CD006201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/49\">",
"      Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374:56.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/hq/2011/a95053_eng.pdf (Accessed on July 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/51\">",
"      Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 191:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/52\">",
"      Barrett MP. The fall and rise of sleeping sickness. Lancet 1999; 353:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/53\">",
"      Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/54\">",
"      Schmid C, Nkunku S, Merolle A, et al. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/55\">",
"      P&eacute;pin J, Milord F, Khonde AN, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/56\">",
"      Mumba Ngoyi D, Lejon V, Pyana P, et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2010; 201:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/57\">",
"      Priotto G, Chappuis F, Bastard M, et al. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis. PLoS Negl Trop Dis 2012; 6:e1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/58\">",
"      Hasker E, Mpanya A, Makabuza J, et al. Treatment outcomes for human African Trypanosomiasis in the Democratic Republic of the Congo: analysis of routine program data from the world's largest sleeping sickness control program. Trop Med Int Health 2012; 17:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/59\">",
"      Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 2001; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/60\">",
"      Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986; 68:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/61\">",
"      Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008; 336:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/62\">",
"      Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007; 195:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/63\">",
"      Alirol E, Schrumpf D, Amici Heradi J, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M&eacute;decins Sans Fronti&egrave;res experience in the Democratic Republic of the Congo. Clin Infect Dis 2013; 56:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/64\">",
"      Gutteridge WE. Existing chemotherapy and its limitations. Br Med Bull 1985; 41:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/65\">",
"      Pepin J, Milord F, Guern C, et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989; 1:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/66\">",
"      Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/67\">",
"      Stewart ML, Krishna S, Burchmore RJ, et al. Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet 2005; 366:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38681/abstract/68\">",
"      Awadzi K. Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis. Filaria J 2003; 2 Suppl 1:S6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5697 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-4D8CED8141-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38681=[""].join("\n");
var outline_f37_49_38681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4241093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2333420\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2334707\">",
"      Early infection (stage I)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2333427\">",
"      - Skin findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2333434\">",
"      - Lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333441\">",
"      Late infection (stage II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333463\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2333470\">",
"      Infection in travelers and expatriates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2358528\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Clinical specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tissue aspirate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibody detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2358752\">",
"      - Molecular tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359067\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2359284\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2359291\">",
"      - T. b. gambiense",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2359298\">",
"      - T. b. rhodesiense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Agents with trypanosomal activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pentamidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4239231\">",
"      - Eflornithine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4239238\">",
"      - Nifurtimox combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Melarsoprol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4239615\">",
"      - Suramin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H269791973\">",
"      - Drugs in the pipeline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4241093\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H769240\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5697|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/3/39986\" title=\"figure 1\">",
"      HAT in endemic and nonendemic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5697|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/21/23902\" title=\"picture 1\">",
"      Elevated plaque with clearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/56/37767\" title=\"picture 2\">",
"      Trypanosomal chancre",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/49/23317\" title=\"picture 3\">",
"      Blood smear African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/32/513\" title=\"picture 4\">",
"      T brucei in blood film",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/3/19515\" title=\"table 1\">",
"      HAT characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/6/19565\" title=\"table 2\">",
"      Clinical signs symptoms HAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/16/12557\" title=\"table 3\">",
"      Laboratory parameters HAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/9/18588\" title=\"table 4\">",
"      Treatment of HAT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17335?source=related_link\">",
"      Antiprotozoal therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=related_link\">",
"      Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38682="Sources of hematopoietic stem cells";
var content_f37_49_38682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sources of hematopoietic stem cells",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/49/38682/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/49/38682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is an important and potentially curative treatment option for a wide variety of malignant and nonmalignant diseases. The pluripotent hematopoietic stem cells required for this procedure are usually obtained from the bone marrow or peripheral blood of a related or unrelated donor. Umbilical cord blood, the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an established alternative source of hematopoietic stem cells in allogeneic HCT.",
"   </p>",
"   <p>",
"    This topic review will discuss the stem cell model of hematopoiesis followed by a discussion of the sources of hematopoietic cells suitable for transplantation. The collection of peripheral blood progenitor cells, the collection of umbilical cord blood, and the selection of an appropriate HCT donor are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=see_link\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of",
"    <span class=\"nowrap\">",
"     progenitor/stem",
"    </span>",
"    cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Sources of stem cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STEM CELL MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and role of hematopoietic stem cells in protecting animals from lethal irradiation became clear in the 1950s. With the development of early in vitro and in vivo assay systems, such as the Till-McCulloch spleen-colony assay, it became clear that there were clonotypic precursor cells capable of giving rise to both erythroid and myeloid lineages of cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/1\">",
"     1",
"    </a>",
"    ]. Hematopoietic stem cells were defined functionally as populations of cells capable of rescuing lethally-irradiated animals, a definition which is accurate conceptually, although difficult to apply in different systems, especially in humans. Nevertheless, it became possible to define a population of cells capable of multilineage repopulation and rescuing animals from lethal irradiation. These stem cells could be re-isolated and used to rescue other lethally irradiated animals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monoclonal antibodies were subsequently developed that recognized proteins on the surface of both immature and mature populations of bone marrow-derived cells. With the refinement of cell sorting technologies, it has been possible to separate populations of cells with stem cell activity. Using this approach, a population of highly purified murine bone marrow-derived stem cells was isolated which was capable of rescuing more than 95 percent of lethally irradiated animals when as few as 100 cells were injected intravenously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Markers on murine stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine stem cells express a marker called stem cell antigen-1 (SCA-1) and have low expression of another marker Thy-1. Furthermore, they do not express proteins normally found on mature myeloid, erythroid, and lymphoid cells (lineage negative). Thus, the phenotype of purified hematopoietic stem cells isolated from murine bone marrow is SCA-1+, Thy-1lo, Lin- [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/2\">",
"     2",
"    </a>",
"    ]. Further refinement of murine hematopoietic stem cells has included expression of c-kit and exclusion of vital dyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cells with this phenotype are present in the murine bone marrow at a frequency of approximately 1:1000 to 1:10,000. They are capable of self renewal and differentiation into progenitor cells which in turn mature into the end-stage cells which are released from the bone marrow. These cells&mdash;red blood cells, neutrophils, monocytes, platelets and lymphocytes&mdash;perform their specialized functions and then die.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Markers on human stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a similar approach, it has been possible to isolate a population of human putative hematopoietic stem cells capable of multilineage growth using in vitro and surrogate in vivo assays. Cells with these functions express the stem cell antigen CD34 and are Lin-; they are also described as being Thy-1lo, Dr-, or CD38-, but the exact phenotype remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A population of CD34 negative hematopoietic stem cells has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], which actively pumps out the vital DNA-binding dye Hoechst 33342 and is capable of reconstituting lethally irradiated animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/6\">",
"     6",
"    </a>",
"    ]. Despite this observation, there is a large volume of clinical data which supports the concept that CD34 expression and the number of CD34+ cells infused correlate closely with the pace of hematopoietic reconstitution both in animals and in humans (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Hematopoietic stem cell mobilization'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Clinical trials using highly purified populations of CD34+, Thy-1+ cells have demonstrated that this cell population alone is capable of rapid and sustained hematopoietic engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, an update shows that these cells alone are capable of supporting long term hematopoiesis following autologous hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical applications of purified hematopoietic stem cells in bone marrow transplantation and gene therapy are quite broad. Using current technology of magnetic bead separation, it is possible to isolate and purify CD34+ cells with high efficiency. Further purification of subpopulations of CD34+ cells (eg, isolating Thy-1+ cells by high speed fluorescence activated cell sorting) is possible but challenging to perform on a clinical scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SOURCES OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cells can be found in several different human tissues: bone marrow; peripheral blood, especially following mobilization; and umbilical vein cord blood obtained at the time of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of bone marrow harvesting has become routine. Bone marrow is generally aspirated from the posterior iliac crests under either regional or general anesthesia. Additional bone marrow can be obtained from the anterior iliac crest; however, the amounts available are relatively limited and this site is generally used only for diagnostic purposes. In patients who have received prior irradiation to the pelvis, it may not be possible to isolate sufficient bone marrow from these sites and alternative sources of hematopoietic stem cells are required.",
"   </p>",
"   <p>",
"    The cell dose required for stable long term engraftment has not been determined with accuracy. A nucleated cell dose of 2 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      8",
"     </sup>",
"     /kg",
"    </span>",
"    is generally considered to be adequate and cell doses of as low as 1 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      8",
"     </sup>",
"     /kg",
"    </span>",
"    have been used, although three retrospective studies indicated that rates of hematopoietic recovery, transplantation-related mortality, and five-year survival were significantly better when the CD34+ cell dose was &ge;3.0 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      6",
"     </sup>",
"     /kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], while rates of hematopoietic recovery were significantly worse when the CD34+ cell dose was &lt;1.2 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      6",
"     </sup>",
"     /kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/12\">",
"     12",
"    </a>",
"    ]. This generally requires between 700 and 1500 mL of bone marrow for an adult recipient. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hematopoietic stem cell mobilization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An alternative to collection of unstimulated bone marrow, which has now become the standard approach in autologous transplant patients, is to prime with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF, Neupogen) prior to bone marrow harvest (10 to 16",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    SQ per day for three days). This has resulted in effective hematopoietic recovery in a study of heavily pretreated patients with poor peripheral blood stem cell mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/13\">",
"     13",
"    </a>",
"    ]. There have been some suggestions that this approach may result in decreased incidence and severity of graft versus host disease. However, this will require validation in larger numbers of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since only a small percentage of the total bone marrow is removed during a harvesting procedure, significant drops in peripheral blood counts do not occur. However, the bone marrow is a highly vascular organ; as a result, there can be substantial blood loss following the harvest, the amount of which depends upon the volume removed. Guidelines established by the National Marrow Donor Program (NMDP) limit the volume of bone marrow removed to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of donor weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow harvest is frequently complicated by mild back or hip pain, fatigue, and transient changes in peripheral blood cell counts. Serious complications of bone marrow harvest are extremely rare and involve mechanical injury, complications of anesthesia, infection, and bleeding.",
"   </p>",
"   <p>",
"    The National Marrow Donor Program (NMDP) has kept careful records of the volunteer donors who have undergone bone marrow collection. In the first 9245 harvests, 125 donors (1.35 percent) experienced a serious medical complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/15\">",
"     15",
"    </a>",
"    ]. Of these, complications thought to be directly related to the procedure resulted in mechanical injury to tissue, bone, or nerve (n=69), anesthetic complications (n=45), infection (n=1), and a grand mal seizure (n=1). The median time to recovery following donation for this population that experienced a serious medical complication was 10 months, but 67 experienced prolonged recovery time.",
"   </p>",
"   <p>",
"    Data regarding less serious, but common, symptoms associated with donation were collected by the NMDP regarding 2505 harvests with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain was the most common acute symptom. On day 2 post-donation, patients reported back",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hip pain (82 percent), throat pain (33 percent), or headache (17 percent). The pain was mild (grade 1) in the majority and resolved in over 80 percent by one month, and by one year the percent of patients with pain (&lt;10 percent) was similar to that seen prior to the procedure.",
"     </li>",
"     <li>",
"      Fatigue was the second most common symptom. On day 2, mild to moderate fatigue was reported in 59 percent of donors, but resolved by one month in the majority (95 percent).",
"     </li>",
"     <li>",
"      Other less common side effects were site reaction, insomnia, nausea, dizziness, and anorexia.",
"     </li>",
"     <li>",
"      Immediately post-donation, most donors experienced an approximately 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease in hemoglobin resulting in the transfusion of at least one autologous red blood cell unit. Hemoglobin remained slightly decreased at one month post-donation, but returned to baseline by one year. In addition, there was an immediate slight increase in white blood cell count (median 9.7 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      interquartile range 7.6 to 12.7) and decrease in platelet count (median 214 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      interquartile range 179 to 252) that returned to baseline by one month post-donation.",
"     </li>",
"     <li>",
"      Median time to full recovery was approximately three weeks. Full recovery was reported by approximately 70 and 95 percent by one and three months, post donation, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of pediatric donors have also demonstrated that bone marrow harvest is safe in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example, the European Group for Blood and Marrow Transplantation Pediatrics Diseases Working Party reported no serious complications among 313 pediatric bone marrow donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the risk of requiring an allogeneic transfusion following bone marrow harvest was highest among patients less than four years old and those requiring a bone marrow harvest volume &gt;20",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    Such patients should be considered for autologous blood donation prior to bone marrow harvest and harvest volumes should not exceed 20",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cells have been detected in the peripheral blood at extremely low levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/19\">",
"     19",
"    </a>",
"    ]. The observation that hematopoietic growth factor administration (eg, granulocyte- macrophage colony-stimulating factor [GM-CSF],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    [G-CSF]), or recovery from cytotoxic chemotherapy results in a 1000-fold or more increase in circulating hematopoietic stem cells has had a major impact on the field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=see_link\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the infusion of these so-called \"mobilized\" human hematopoietic stem cells and progenitor cells, recovery is hastened; this has had a significant impact on the safety and tolerability of autologous transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/22\">",
"     22",
"    </a>",
"    ]. The collections used at most institutions contain a mixture of stem cells and progenitor cells and will be referred to as peripheral blood progenitor cells (PBPCs) to differentiate them from studies in which only the purified human hematopoietic stem cells were infused.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8516461\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood progenitor cells (PBPCs) account for the majority of unrelated donor hematopoietic stem cells. The complication rate appears to be very low. Potential risks for the donor include those related to the administration of G-CSF and to apheresis. Rarely, patients who receive G-CSF can develop splenomegaly with risk of splenic rupture. In our experience, we can perform most apheresis collections without central venous access.",
"   </p>",
"   <p>",
"    In a prospective study of first-time unrelated donors from 2004 to 2009 by the National Marrow Donor Program (NMDP), 6768 of 9494 (71 percent) donations were PBPCs collected over one (73 percent) or two days of apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/23\">",
"     23",
"    </a>",
"    ]. Central venous access was required for 21 percent of women and 5 percent of men. Less than 3 percent were hospitalized. The following complications were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients experienced mild to moderate (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      generalized musculoskeletal pain within 24 hours of G-CSF administration. This pain peaked around day 5 and usually returned to baseline within one week.",
"     </li>",
"     <li>",
"      The most common apheresis-related toxicity was numbness or tingling that was transient (33 to 45 percent), persistent moderate (2 to 8 percent), or severe (&lt;1 percent). Tetany occurred in &lt;1 percent. Other toxicities included nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting (&lt;2 percent) and mild to moderate local intravenous site infections (&lt;1 percent).",
"     </li>",
"     <li>",
"      Changes in peripheral blood counts were common. Most recovered to near-normal levels within one month. Leukocytosis occurred following G-CSF administration while thrombocytopenia and anemia occurred following apheresis. On day 5 after G-CSF administration, the mean white blood cell count was approximately 40 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      with 20 percent above 50 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      and one donor above 100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L.",
"      </span>",
"      Following a single day of apheresis, platelets decreased to &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      in 26 percent and &lt;50 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      in &lt;1 percent. After two days of apheresis, platelets were &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      and &lt;50 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      in 50 and 1 percent, respectively. Platelets did not decrease to &lt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      in any cases and no platelet transfusions were required. Significant anemia (hemoglobin &lt;8",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      occurred in 0.1 and 0.2 percent of men and women, respectively.",
"      <br/>",
"      <br/>",
"      More than half of patients reported resolution of toxicities by one week post-collection. Rates of complete recovery at 1 and 6 months were &gt;90 and 100 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63572418\">",
"    <span class=\"h2\">",
"     Umbilical cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively high numbers of hematopoietic stem cells are present in umbilical cord blood (UCB) collected at the time of delivery. These cells can be processed and cryopreserved in cord blood banks. Units can be searched similar to the way that unrelated donors are identified. Following HLA-matching to a recipient, the cord blood unit can be transported to the transplant center with minimal delay and used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unrelated UCB offers many practical advantages over unrelated donor bone marrow or mobilized peripheral blood progenitor cells as a source of hematopoietic stem cells, including an expanded donor pool, ease of procurement and lack of donor attrition, and decreased graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604479#H61604479\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Advantages and limitations of cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations to UCB include an increased risk of graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39145?source=see_link\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC STEM CELL MOBILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal methodology for mobilizing peripheral blood progenitor cells (PBPCs) has yet to be defined, and several different approaches have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The standard method has been to treat the donor with G-CSF at a dose of 10 to 16",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day, with hematopoietic stem cell mobilization usually occurring between days four and six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. In one randomized study, G-CSF was given either in a single daily dose of 10",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    or in divided doses of 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    twice per day to normal donors undergoing collection for allogeneic transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/31\">",
"     31",
"    </a>",
"    ]. The latter strategy led to a higher yield of CD34+ cells and required fewer apheresis procedures, without increasing toxicity or cost. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\", section on 'Stem cell and progenitor cell mobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute number of CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    of recipient weight has proven to be the most reliable and practical method for determining the adequacy of a PBPC product. Hematopoietic colony assays correlate with CD34+ cell assays; however, they are cumbersome to perform, difficult to standardize, and may require 10 or more days for readout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. As a result, the standard method used in most laboratories is to measure the CD34+ cell content by fluorescence activated cell sorting (FACS). A major effort has been made to standardize and validate this process among different laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of peripheral blood CD34+ cells has been used to predict the ability of G-CSF alone or the combination of G-CSF plus chemotherapy to mobilize a sufficient number of PBPC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. In one study, the minimum steady-state concentration in the peripheral blood required to assure, with 95 percent probability, the successful mobilization and collection of &gt;2.5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    was 1.4 and 8.9 CD34+",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for patients with multiple myeloma and non-Hodgkin lymphoma, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/35\">",
"     35",
"    </a>",
"    ]. In two studies involving patients with a variety of malignancies, a prepheresis concentration of &gt;34 or &gt;40 CD34+",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    assured collection by a single conventional-volume leukapheresis of &gt;2.5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    in 88 and 100 percent of subjects, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, measuring CD34+ cells in the peripheral blood, especially when present at low levels, can be associated with significant error. Therefore, it is important that this assay is validated appropriately.",
"   </p>",
"   <p>",
"    A kinetic model of CD34+ cell mobilization and harvest has been developed, with variables including the patient's sex, height, and weight (to calculate total blood volume), CD34+ cell count in the peripheral blood, collection flow rate, and the planned duration of harvest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/41\">",
"     41",
"    </a>",
"    ]. The probability that the measured yield was 90 percent or more of the predicted value was 94 and 90 percent for autologous and allogeneic collections, respectively. This model is now being tested at multiple institutions and with different cell separators to determine its general applicability.",
"   </p>",
"   <p>",
"    The relationship between donor age and CD34+ cell mobilization is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the administration of G-CSF to donors &lt;18 years of age (range 1 to 17) lead to CD34+ mobilization in a pattern similar to that observed in donors &ge;18 years of age, although a significantly higher percent of younger patients reached the targeted cell dose with only one apheresis (56 versus 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/44\">",
"       44",
"      </a>",
"      ]. A phase II study found a single dose of pegylated G-CSF (100",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      resulted in adequate mobilization in 83 percent of children &lt;18 years undergoing peripheral blood progenitor cell collection for autologous transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective analysis of 129 consecutive related adult donors, factors affecting circulating CD34+ cell counts as a surrogate marker for stem cell mobilization included donor weight and total G-CSF dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/46\">",
"       46",
"      </a>",
"      ]. No difference was found for the 44 donors age &ge;55 when compared with the 85 donors &lt;55 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of interest, the oldest donor that we have successfully collected was 85 years of age at the time of collection.",
"   </p>",
"   <p>",
"    Following infusion of the mobilized PBPCs, hematopoietic reconstitution is rapid, requiring approximately 8 to 10 days for neutrophil recovery and 10 to 12 days for platelet recovery. The CD34+ cell",
"    <span class=\"nowrap\">",
"     dose/kg",
"    </span>",
"    has proven to be a useful value, since patients who receive more than 2 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     CD34+cells/kg",
"    </span>",
"    generally have rapid and sustained hematopoietic recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/27,29,47\">",
"     27,29,47",
"    </a>",
"    ]. Thus, this cell dose defines an adequate collection of PBPCs which generally ensures rapid reconstitution. However, there is no established minimal dose. Many centers have accepted CD34+ cell doses of",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      6",
"     </sup>",
"     /kg,",
"    </span>",
"    although such doses have often been associated with prolonged platelet recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Optimal CD34 cell dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giving larger doses of CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    may result in slightly faster platelet recovery following hematopoietic cell transplantation, may have a minimal effect on neutrophil recovery, and a possibly favorable effect on overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/48-55\">",
"     48-55",
"    </a>",
"    ]. In one study, there was a significant inverse correlation between infused CD34+ cell count and the time to recovery of an absolute lymphocyte count",
"    <span class=\"nowrap\">",
"     &ge;500/microL",
"    </span>",
"    in patients with non-Hodgkin lymphoma following autologous HCT, along with significantly longer event-free and overall survivals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"optimal\" CD34+ cell dose has yet to be defined, as attested to by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/55,57-60\">",
"     55,57-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial comparing mobilization with G-CSF, GM-CSF or a combination of both cytokines with chemotherapy has been performed in 156 patients with breast cancer, lymphoma or multiple myeloma. Patients who received G-CSF either alone or in combination with GM-CSF had significantly higher yields of CD34+ cells (median 7.1 versus 2.0 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        6",
"       </sup>",
"       /kg",
"      </span>",
"      per apheresis). A significantly higher percentage of patients achieved a dose of 2.5 X 10",
"      <sup>",
"       6",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      (94 percent versus 78 percent). Although engraftment was more rapid with the higher dose of CD34+ cells, there were no major differences in long term outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, a CD34+ dose &gt;8 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      was associated with an increased risk of clinically extensive chronic GVHD following allogeneic transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/52\">",
"       52",
"      </a>",
"      ]. However, these observations have not been made by other transplant groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of leukemic patients receiving HLA-identical sibling HCT, the risk of grade II-IV acute GVHD did not differ with low versus high CD34+ cell doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/63\">",
"       63",
"      </a>",
"      ]. The risk of chronic GVHD was increased only in the group of patients transplanted with PBPCs who had a Karnofsky score of 90 percent at the time of transplant. Although there was no effect on overall mortality, treatment failure was significantly reduced for those receiving the higher cell doses. Their data suggested that an \"optimal\" CD34+ cell dose for bone marrow or PBPCs was &gt;3 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        6",
"       </sup>",
"       /kg",
"      </span>",
"      and &gt;6 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        6",
"       </sup>",
"       /kg,",
"      </span>",
"      respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective studies will be required in order to define the optimal dose of CD34+ cells, CD34+ subsets, total nucleated cell dose, and other graft components (see",
"    <a class=\"local\" href=\"#H20\">",
"     'T cell dose'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/64-68\">",
"     64-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inadequate G-CSF response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of G-CSF alone results in successful mobilization of peripheral blood progenitor cells (PBPCs) in the majority of patients. The optimal dose of G-CSF is the subject of ongoing investigation (see below), but a higher dose (&gt;10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) may yield a greater content of CD34+ cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/69\">",
"     69",
"    </a>",
"    ]. However, some patients are difficult to adequately mobilize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/70\">",
"     70",
"    </a>",
"    ]. Why this occurs is not known, but the degree of prior exposure to chemotherapy or irradiation or the underlying diagnosis may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/38,71\">",
"     38,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, prior exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in patients with multiple myeloma, especially for more than four to six months, was associated with decreased ability to successfully collect PBPCs mobilized with G-CSF alone, which could be overcome with the use of chemotherapy plus G-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/72\">",
"     72",
"    </a>",
"    ]. Despite these observations, it has been extremely difficult to predict which patients will be poor mobilizers prior to initiating the mobilization procedure.",
"   </p>",
"   <p>",
"    One approach to these patients is to increase the G-CSF dose. In two studies, doses between 20 to 50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day improved the CD34+ cell yield, thereby reducing the number of days of apheresis required to reach the collection goal of more than 2.5 or 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. Other hematopoietic growth factors also have been used to mobilize PBPCs. These include GM-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/74\">",
"     74",
"    </a>",
"    ], interleukin (IL)-3, the synthetic IL-3 agonist SC-55494, and the CXCR4 inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"     plerixafor",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Other mobilizing agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other growth factors have been evaluated for the purpose of stem cell mobilization. Stem cell factor (SCF, Steel factor, c-kit ligand) has been extensively evaluated for the purpose of hematopoietic stem cell mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/75\">",
"     75",
"    </a>",
"    ]. SCF also activates mast cells, producing serious side effects; however, this problem has been manageable in the clinical trials performed to date. Although SCF alone has relatively limited activity, combination therapy with G-CSF produces a statistically significant increase in the percentage of patients who were successfully mobilized using the threshold CD34+ cell dose of 5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      6",
"     </sup>",
"     /kg",
"    </span>",
"    to define a successful mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/48\">",
"     48",
"    </a>",
"    ]. SCF is approved for this use in a number of countries, but not in the United States.",
"   </p>",
"   <p>",
"    A growth factor similar to SCF in biologic function called flt3 ligand has also been explored in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/75\">",
"     75",
"    </a>",
"    ]. This growth factor has the added and possibly extremely useful advantage that it also induces significant dendritic cell mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Flt3 ligand does not activate mast cells. Another potential early growth factor is thrombopoietin which appears to increase marrow hematopoietic progenitors and peripheral CD34+ cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16680?source=see_link\">",
"     \"Biology and physiology of thrombopoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, the development of thrombopoietin and the closely related cytokine megakaryocyte growth and development factor (MGDF) was halted when these agents resulted in significant antibody formation, resulting in transient thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21466?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Antibody formation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other mobilizing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cells express a wide range of cell adhesion molecules (eg, integrins, selectins), while bone marrow stromal cells express the ligands of many of these adhesion molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/81\">",
"     81",
"    </a>",
"    ]. Stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 play a key role in the \"trafficking\" of PBPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Interruption of these and other interactions might therefore result in the release (ie, mobilization) of highly functional PBPCs into the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small pilot study involving 16 patients failing a first attempt at mobilization following G-CSF plus chemotherapy, repeat treatment with G-CSF, chemotherapy, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH, 100",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day) resulted in successful mobilization in 15 of the 16 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/85\">",
"     85",
"    </a>",
"    ]. Transient insulin-requiring hyperglycemia was seen in two patients, with no apparent adverse effect on the patients' underlying malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Plerixafor (AMD3100, Mozobil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal cell-derived factor 1 (SDF-1) binds to the receptor CXCR4, which has been identified as an important mechanism of stem cell binding within the hematopoietic microenvironment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/86\">",
"     86",
"    </a>",
"    ]. An inhibitor of this interaction between CXCR4 and SDF-1 has been developed and termed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"     plerixafor",
"    </a>",
"    (Mozobil or AMD3100).",
"   </p>",
"   <p>",
"    Initial phase I studies were performed in patients with multiple myeloma and non-Hodgkin lymphoma at doses of 160 and 240",
"    <span class=\"nowrap\">",
"     mcg/kg.",
"    </span>",
"    A rapid rise in peripheral blood CD34+ cells was noted four to six hours after injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/87\">",
"     87",
"    </a>",
"    ]. The drug was generally well tolerated with only minimal side effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of G-CSF plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      has been shown to improve mobilization of CD34+ cells in subjects who had previously failed mobilization with chemotherapy or cytokine-only mobilization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/88\">",
"       88",
"      </a>",
"      ] and was superior to G-CSF alone in the mobilization of more than 5 x 10",
"      <sup>",
"       6",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg,",
"      </span>",
"      requiring fewer apheresis procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/89,90\">",
"       89,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase III randomized, placebo-controlled study in 298 patients with non-Hodgkin lymphoma requiring autologous HCT, a significantly higher proportion of subjects treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      plus G-CSF achieved the optimal CD34+ cell target for HCT in fewer apheresis days, compared with G-CSF alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"       plerixafor",
"      </a>",
"      was given to 25 HLA-matched sibling HCT donors (240",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      subcutaneously) without G-CSF and leukopheresis initiated four hours later. A CD34+ cell dose sufficient for transplantation was achieved in two-thirds of the donors after a single dose of AMD3100 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/92\">",
"       92",
"      </a>",
"      ]. No donor experienced more than grade 1 toxicity and no unexpected adverse events were observed in any of the recipients. All patients engrafted in a timely fashion following infusion of the mobilized product and no differences were noted in the incidence or severity of GVHD. Larger studies of normal donors are needed using this approach before it can be routinely recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"     Plerixafor",
"    </a>",
"    is also a potent and rapid mobilizer of endothelial progenitor and angiogenic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/93\">",
"     93",
"    </a>",
"    ]. In an animal model, plerixafor-mobilized CD34+ cells included more B-, T-, and mast cell precursors, while G-CSF-mobilized CD34+ cells had more neutrophil and mononuclear phagocyte precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States FDA has approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"     plerixafor",
"    </a>",
"    (Mozobil) for use in combination with G-CSF to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. For many groups, the routine use of plerixafor is cost prohibitive and generally reserved for patients who fail to mobilize adequate numbers of CD34+ cells with either G-CSF or G-CSF plus chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H3#H3\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Collection of stem cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mobilization after chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobilization of peripheral blood progenitor cells (PBPCs) is also observed after recovery from cytotoxic chemotherapy. The addition of growth factors such as G-CSF results in a synergistic effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/99-103\">",
"     99-103",
"    </a>",
"    ]. A variety of mobilization schemas have been developed which exploit this phenomenon, such as combining chemotherapy with G-CSF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    , or GM-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/101,102,104-108\">",
"     101,102,104-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard approach is to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (typically 4",
"    <span class=\"nowrap\">",
"     gm/m(2))",
"    </span>",
"    along with G-CSF 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    (rounded to the nearest vial size). This approach has been safely and consistently applied to a number of different disease settings with relatively few toxicities and excellent collection of CD34+ cells.",
"   </p>",
"   <p>",
"    Successful mobilization of PBPCs has also been accomplished during the recovery period following high-dose chemotherapy and autologous hematopoietic cell transplantation, in order to obtain sufficient PBPCs for a second (tandem) autologous transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/104\">",
"     104",
"    </a>",
"    ]. The number of PBPCs obtained in this manner may be related to the CD34+ cell dose transfused in the preceding autograft.",
"   </p>",
"   <p>",
"    A peak value of &gt;10 circulating CD34+",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    during recovery post-chemotherapy has been used to predict successful PBPC mobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, in patients receiving G-CSF while recovering from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based chemotherapy (FLAN: fludarabine, cytosine arabinoside, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ), only 6 of 19 could be successfully harvested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/38\">",
"     38",
"    </a>",
"    ]. The remaining 13 patients did not reach the peak number of 10 CD34+",
"    <span class=\"nowrap\">",
"     cells/microL;",
"    </span>",
"    10 of these patients received a second course of G-CSF stimulation and all failed to respond",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be successfully harvested.",
"   </p>",
"   <p>",
"    The general impression that mobilization following chemotherapy plus growth factors is superior to growth factors alone is supported by a crossover trial, in which each of 29 patients was randomly assigned to receive two different progenitor cell mobilizations in random order, separated by a two-week washout period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/101\">",
"     101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G regimen &mdash; GM-CSF on days 1 to 12 plus G-CSF on days 7 to 12",
"     </li>",
"     <li>",
"      C regimen &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      on day 1 (plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) followed by G-CSF on days 3 to 14",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The C regimen resulted in mobilization of 2.7-fold more CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    than the G regimen (p&lt;0.01). As a result, the ability of the C and G regimens to mobilize &ge;2 x 106 CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    during the first mobilization was 90 and 50 percent, respectively. The C regimen was successful in reaching this target in three of seven subjects in whom the G regimen failed. Conversely, the G regimen failed to reach this target in 7 of 10 subjects in whom the C regimen was successful. Thirty percent of the patients given the C regimen were admitted to the hospital because of neutropenic fever, for a median duration of four days; there were no deaths. Estimated hospital charges were similar for the two regimens.",
"   </p>",
"   <p>",
"    In another study, 47 heavily-pretreated patients with relapsed or refractory lymphoma received combination chemotherapy; those with sensitive or stable disease were randomly assigned to receive G-CSF alone (arm A) or G-CSF plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (arm B), followed by collection of PBPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/102\">",
"     102",
"    </a>",
"    ]. Subjects in arm A received the same dose of cyclophosphamide following PBPC collection; both groups then received identical chemotherapy, involved field radiotherapy, and preparative regimens, followed by administration of the collected PBPCs. Although PBPC mobilization following the addition of chemotherapy (arm B) resulted in higher CD34+ cell collection, there were no differences in median time to engraftment of neutrophils or platelets, tumor cell contamination, overall or progression-free survival, resource utilization, or toxicity between the two study arms.",
"   </p>",
"   <p>",
"    The addition of chemotherapy can result in complications, such as febrile neutropenia and hemorrhagic cystitis, but can also provide additional cytoreduction for patients with malignancies. The combination of chemotherapy with growth factors is only appropriate in the autologous transplant setting. One potential concern comes from a report of 612 patients who received autologous stem cell transplantation for lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/105\">",
"     105",
"    </a>",
"    ]. The estimated cumulative probability of developing morphologic therapy-related myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/acute",
"    </span>",
"    myeloid leukemia was 8.6 percent at six years. The relative risk of this complication was 7.7 in patients who received stem cell priming with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    To test the relative effectiveness of G-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    ) and GM-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ) in this setting, 158 patients with breast cancer, lymphoma, or multiple myeloma were given chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . Patients were then randomly assigned to receive G-CSF alone (6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day), GM-CSF alone (250",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), or GM-CSF for five days followed by G-CSF, starting on the day after completion of the chemotherapy. Compared with those who received GM-CSF, patients who received G-CSF had the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/61,109\">",
"     61,109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Faster recovery of an absolute neutrophil count to",
"      <span class=\"nowrap\">",
"       &ge;500/microL",
"      </span>",
"      (11 versus 14 days)",
"     </li>",
"     <li>",
"      Fewer patients requiring red cell transfusions",
"     </li>",
"     <li>",
"      Fewer patients with fever (18 versus 52 percent)",
"     </li>",
"     <li>",
"      Fewer hospital admissions (20 versus 42 percent)",
"     </li>",
"     <li>",
"      Less intravenous antibiotic therapy",
"     </li>",
"     <li>",
"      Higher yields of CD34+ cells (7.1 versus 2.0 x 10",
"      <sup>",
"       6",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      per apheresis procedure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that G-CSF alone or sequential GM-CSF and G-CSF were superior to GM-CSF alone for mobilization of PBPCs and reduction of toxicity after mobilization with chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mobilized bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of G-CSF-mobilized bone marrow has been explored with the hypothesis that this might yield higher numbers of progenitor cells in subjects unable to mobilize sufficient numbers of peripheral blood hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/110\">",
"     110",
"    </a>",
"    ]. It might also reduce the risk of GVHD. A relatively small randomized study has suggested that the use of G-CSF primed bone marrow may result in such benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/14,111\">",
"     14,111",
"    </a>",
"    ]. Larger randomized studies testing this hypothesis are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RELATIVE EFFICACY OF PBPC VERSUS BONE MARROW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two studies, patients with relapsed lymphoma were randomly assigned to receive either autologous peripheral blood progenitor cells (PBPCs) or bone marrow (BM) following induction treatment; PBPCs were found to be superior with regard to engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/112\">",
"     112",
"    </a>",
"    ], supportive care, quality of life, and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. However, there were no differences in disease-free survival between the two groups in either of the two studies.",
"   </p>",
"   <p>",
"    A retrospective, non-randomized analysis reviewed this issue in 2165 patients who received an autologous HCT (1607 PBPCs and 558 BM) during the period from 1994 to 2006 for acute myeloid leukemia during a first complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/115\">",
"     115",
"    </a>",
"    ]. In a multivariate analysis, the incidence of disease relapse was significantly higher for those receiving PBPCs either &le;80 days (56 percent) or &gt;80 days after achievement of CR1 (46 percent) than for those receiving BM (39 percent).",
"   </p>",
"   <p>",
"    While these types of analyses are important for hypothesis generation, a prospective, randomized study would be required to definitively demonstrate superiority of one source over another. In any event, most transplant centers now utilize mobilized PBPCs exclusively for autologous transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PBPCs have gained wide acceptance in allogeneic transplantation for reasons that will be discussed below. The collection of PBPCs for this purpose has largely been accomplished after mobilization with G-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Sufficient numbers of CD34+ cells are collected in the majority of patients without difficulty, although the optimal and required number of CD34+ cells for allogeneic transplantation has not been determined. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hematopoietic stem cell mobilization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Both nonrandomized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/119-123\">",
"     119-123",
"    </a>",
"    ] and randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/14,124-130\">",
"     14,124-130",
"    </a>",
"    ] have attempted to determine whether PBPCs or bone marrow is the superior source of hematopoietic stem cells in the allogeneic setting. These trials have produced conflicting results, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large nonrandomized study from the EMBT studied the effect of bone marrow cell dose in 881 adult patients with AML transplanted in first CR using high-dose (&gt;2.7 x 10",
"      <sup>",
"       8",
"      </sup>",
"      <span class=\"nowrap\">",
"       cells/kg)",
"      </span>",
"      or low-dose (&lt;2.7 x 10",
"      <sup>",
"       8",
"      </sup>",
"      <span class=\"nowrap\">",
"       cells/kg)",
"      </span>",
"      bone marrow or PBPC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/131\">",
"       131",
"      </a>",
"      ]. There was no difference between PBPC and low-dose bone marrow in terms of treatment-related mortality, leukemia-free survival, or overall survival. In contrast, high-dose bone marrow compared to PBPC was associated with significantly lower treatment-related mortality and better leukemia-free and overall survival. Marrow at high or low dose induced less chronic GVHD than PBPC.",
"     </li>",
"     <li>",
"      A randomized trial involved 350 patients with acute leukemia in first remission or chronic myeloid leukemia in first chronic phase, and confirmed the more rapid recovery of platelets and neutrophils seen in all prior studies utilizing PBPCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/126\">",
"       126",
"      </a>",
"      ]. PBPCs were associated with significant increases in the incidence of grades II-IV acute GVHD (52 versus 39 percent, odds ratio 1.74, 95% CI 1.1-2.7), and chronic GVHD (67 versus 54 percent, OR 1.7, 95% CI 1.2-2.4). Estimated survival at two years was 65 percent with either source of stem cells.",
"     </li>",
"     <li>",
"      In another randomized trial, 228 patients &lt;65 years of age with CML, AML, or MDS were assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      - mobilized PBPCs or bone marrow from an HLA-matched sibling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/127\">",
"       127",
"      </a>",
"      ]. PBPC transplantation was associated with a significantly shorter time to recovery of a platelet count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"      (by six days) and an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"      (by four days). The two groups had identical rates of grades II to IV acute GVHD (44 percent), and similar rates of extensive chronic GVHD. The probability of overall survival at 30 months was significantly higher for recipients of PBPCs (68 versus 60 percent, hazard ratio 0.62, 95% CI: 0.39-0.97).",
"     </li>",
"     <li>",
"      In a phase III trial, 551 adults undergoing allogeneic HCT from HLA-matched unrelated donors were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       filgrastim",
"      </a>",
"      -mobilized PBPCs or bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/132\">",
"       132",
"      </a>",
"      ]. At a median follow-up of 36 months, those assigned to PBPCs demonstrated a significantly shorter median time to platelet (by seven days) and neutrophil (by five days) count recovery, a lower incidence of graft failure (3 versus 9 percent), similar rates of acute GVHD, but increased rates of chronic extensive GVHD (48 versus 32 percent), a lower percentage of patients off GVHD therapy by two years (37 versus 57 percent), and a similar overall survival at two years (51 versus 46 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is not yet compelling evidence for the superiority of PBPCs over bone marrow for allogeneic HCT in the adult, while two retrospective studies found PBPCs to be inferior to bone marrow in children and adolescents with acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/133\">",
"     133",
"    </a>",
"    ] or severe aplastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/134\">",
"     134",
"    </a>",
"    ]. While most studies and a meta-analysis have concluded that hematopoietic and early immunohematologic reconstitution is significantly more rapid following use of PBPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/121,135,136\">",
"     121,135,136",
"    </a>",
"    ], acute and chronic (extensive) GVHD may be more common following PBPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/123,129,136-139\">",
"     123,129,136-139",
"    </a>",
"    ], although perhaps associated with a beneficial graft-versus-tumor effect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improved long-term outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/124,127,136,139,140\">",
"     124,127,136,139,140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a nine-year follow-up study of a randomized trial, overall and leukemia-free survival were similar in 329 leukemia patients who underwent HCT using PBPCs or bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/129\">",
"     129",
"    </a>",
"    ]. While significant differences in the incidence of chronic GVHD and the duration of immunosuppression were noted, survival, general health, and the incidence of late events were not adversely affected.",
"   </p>",
"   <p>",
"    One approach adopted by many centers is to utilize mobilized PBPCs for advanced stage patients and BM for standard risk patients. Together, these results suggest that both PBPC and bone marrow are acceptable stem cell sources. A choice among these must be made dependent upon patient and donor preference. PBSC may be preferred for those at high risk of graft failure or infections in the early post-transplantation period where more rapid hematopoietic recovery could be a particular advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER TRANSPLANT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     T cell dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies have focused on the mobilization of human hematopoietic stem and progenitor cells. However, other cell populations may be clinically important, such as conventional CD4+ and CD8+ T cells (including different subsets such as naive and memory T cells), NK cells, and regulatory T cells, which may modify the graft-versus-tumor effect, the risk of GVHD,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the risk of graft rejection in the allogeneic setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/57,58,141-144\">",
"     57,58,141-144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In murine studies, for example, the T cells mobilized following G-CSF administration are functionally different with respect to cytokine production and have less ability to cause GVHD than the T cells present in unmobilized peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/145\">",
"     145",
"    </a>",
"    ]. Two clinical observations are of interest in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of HLA-identical sibling transplants of G-CSF-mobilized PBPCs, the actuarial probability of graft failure progressively increased as the number of CD3+ T cells in the graft decreased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/146\">",
"       146",
"      </a>",
"      ], while the incidence of acute GVHD increased with increasing T cell dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase I-II clinical trial, removal of CD8+ T cells was associated with an increased risk of rejection of HLA-mismatched (ie, HLA-DRB1 or -A or -B disparity) bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/147\">",
"       147",
"      </a>",
"      ]. Conversely, the risk of grades III-IV GVHD was higher than 15 percent at any dose of CD8+ cells associated with a risk of graft failure less than 5 percent. Removal of CD4+ T cells was not associated with increased graft rejection or an appreciable decrease in the risk of grades III-IV GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been much interest in the role of T cells capable of regulating immune responses. These cells are termed regulatory T cells or Treg and are defined by their ability to inhibit the mixed lymphocyte reaction. Although the field of regulatory T cell biology is complex, there are several issues relevant to this discussion.",
"   </p>",
"   <p>",
"    The best characterized Treg population of Treg has the cell surface phenotype",
"    <span class=\"nowrap\">",
"     CD4+/CD25+",
"    </span>",
"    and expresses the transcription factor FoxP3. These cells also have low expression of CD127 (IL7R). In murine models, adjusting the ratio of Treg to conventional CD4+ and CD8+ T cells has resulted in reduced GVHD with retention of graft versus tumor effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/148-150\">",
"     148-150",
"    </a>",
"    ]. Patients with higher numbers of FoxP3-expressing Treg cells have a lower risk of GVHD than patients with lower numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/151\">",
"     151",
"    </a>",
"    ], although direct clinical correlations have not been found in all studies of unselected grafts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of graft-versus-host disease\", section on 'Regulatory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to Tregs, there are other populations of cells, such as NK-T cells and TR-1 cells, which are also capable of regulating immune responses and have shown promise in preclinical models. Early investigation in patients is underway of this novel approach to GVHD modulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mobilization of other cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mobilization of other accessory cells, such as dendritic cells, has been studied to only a limited extent. As noted above, the observation that flt ligand mobilizes both CD34+ cells and dendritic cells could have important clinical implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Tumor cell contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of tumor cells in the mobilized peripheral blood progenitor cell (PBPC) collections and the clinical significance of this finding have generated considerable debate. There is no doubt that tumor cell contamination of PBPC collections can occur. In one study using a quantitative polymerase chain reaction (PCR) technique, the lymphoma cell burden difference between bone marrow and peripheral blood was measured at less than one log [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/152\">",
"     152",
"    </a>",
"    ]. Since the absolute number of cells infused with an unmanipulated PBPC graft is often 1 to 1.5 logs more than with a bone marrow graft, the total number of tumor cells infused in absolute terms may be similar with these two hematopoietic stem cell sources (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Tumor cell purging'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Studies have shown increased relapse rates among patients with acute myeloid leukemia who undergo an autologous transplant with mobilized PBPC infusion rather than bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/115\">",
"     115",
"    </a>",
"    ]. Further evaluation of PBPC samples demonstrated that AML patients infused with a higher CD34 positive cell dose (a marker found both on leukemic and normal progenitors) were more likely to relapse than those infused with a lower CD34 positive cell dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a similar concern with autologous stem cell transplants in patients with multiple myeloma. In a xenotransplant mouse model, injection of peripheral cells from patients with aggressive myeloma or G-CSF mobilized cells from patients with minimal myeloma resulted in the development of myeloma (including lytic bone lesions) in the recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/154\">",
"     154",
"    </a>",
"    ]. This observation suggests that purging these cells prior to transplantation might be beneficial.",
"   </p>",
"   <p>",
"    With newer mobilization strategies, such as the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/12/27844?source=see_link\">",
"     plerixafor",
"    </a>",
"    , these issues continue to be important and require further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Tumor cell purging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of tumor cell purging in the setting of an autologous transplant procedure has generated significant debate. A number of retrospective studies have suggested that the infusion of products containing tumor cells is associated with higher rates of relapse. The following observations are compatible with a beneficial effect from tumor cell purging when bone marrow is used as the source of stem cells, especially in diseases that typically infiltrate the bone marrow such as leukemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with acute leukemia, ex vivo treatment with the activated form of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (4-hydroperoxy- cyclophosphamide [perfosfamide]) or the related drug mafosfamide has been associated with a lower relapse rate than seen in patients who received unmanipulated bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/155-158\">",
"       155-158",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have fewer than 1 percent of pretreatment hematopoietic progenitor colonies (CFU-GM) following the purging procedure have had a lower rate of relapse and improved leukemia-free survival (12 versus 36 percent in those with more than 1 percent CFU-GM in one series), suggesting that the intensity of bone marrow purging had an impact on relapse rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/159\">",
"       159",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies did not actually measure the tumor burden. The degree of purging was thought to be indirectly assessed by the cytotoxicity towards normal hematopoietic colony cells.",
"   </p>",
"   <p>",
"    Routine radiographic and pathologic studies are relatively crude indicators of disease burden. As a result, an extensive array of techniques has been developed in an effort to sensitively detect residual tumor burden. These include the use of clonogenic assays, fluorescence-activated cell sorting analysis, immunofluorescence (IF), fluorescence in situ hybridization (FISH)-based assays and the polymerase chain reaction (PCR).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonogenic assays are sensitive and specific; the major limitation is that primary tumor cells fail to grow in many instances.",
"     </li>",
"     <li>",
"      The IF and PCR based assays are the most sensitive and have been used in a variety of clinical situations. One study of patients with non-Hodgkin lymphoma, for example, used PCR for the t(14;18) chromosomal translocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/160\">",
"       160",
"      </a>",
"      ]. In a retrospective analysis of 114 patients who were tumor cell positive by PCR prior to immunologic purging with a panel of monoclonal antibodies (Mab) and rabbit complement, the 57 patients who were successfully purged to PCR-negative had a dramatically reduced rate of subsequent relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/160\">",
"       160",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive data for the concept that tumor cell contamination can lead to subsequent relapse comes from direct gene marking studies in which bone marrow products were exposed to a retrovirus that could be readily detected by PCR following infusion. In some patients who were transplanted for neuroblastoma or acute or chronic myeloid leukemia, tumor cells containing the retrovirus could be detected following relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/161,162\">",
"     161,162",
"    </a>",
"    ]. Despite these suggestive data, there have been no prospective, randomized clinical trials directly assessing the role of purging in autologous bone marrow transplantation.",
"   </p>",
"   <p>",
"    With the emergence of PBPCs as the preferred source of stem cells for autologous transplantation, there were initial hopes that this source of cells would be less contaminated than bone marrow. Although this appears to be true in some cases, it is clear that PBPCs are frequently contaminated with tumor cells in a variety of diseases and that the number of tumor cells infused may be similar to that with bone marrow as the source (see above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several approaches have been employed in an effort to deplete tumor cells from the PBPC products. One has been to enrich for CD34+ progenitor cells and deplete tumor cells passively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/163\">",
"     163",
"    </a>",
"    ]. An alternative methodology uses an enrichment step for CD34+ cells followed by tumor cell depletion with monoclonal antibodies and complement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/47\">",
"     47",
"    </a>",
"    ], column-based techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/164\">",
"     164",
"    </a>",
"    ], or immunomagnetic beads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/165\">",
"     165",
"    </a>",
"    ]. Further purification of human stem cells has also been pursued by selecting for CD34+ cells which coexpress Thy-1 by FACS.",
"   </p>",
"   <p>",
"    These methods are effective in significantly reducing the tumor cell burden in many different clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/166\">",
"     166",
"    </a>",
"    ]. However, further studies are required to demonstrate that in vivo or in vitro reduction in tumor cell burden translates into improved disease free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/167\">",
"     167",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12058?source=see_link&amp;anchor=H4#H4\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'In vitro tumor cell purging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33178?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Stem cell collection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ex vivo expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ex vivo expansion of hematopoietic stem cells and committed progenitor cells is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\", section on 'Ex vivo expansion of stem and progenitor cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Embryonic stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;When co-cultured with murine bone marrow or yolk sac endothelial cell lines, along with fetal bovine serum, human embryonic stem cells (blastocysts) can differentiate into CD34+ hematopoietic precursor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/168\">",
"     168",
"    </a>",
"    ]. When these precursor cells are cultured on semisolid media along with hematopoietic growth factors, they form characteristic myeloid, erythroid, and megakaryocyte colonies. Such embryonic stem cells, which can be maintained indefinitely in culture, may ultimately provide another source of hematopoietic stem cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their progeny for use in transfusion and transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/169,170\">",
"     169,170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INFUSION OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infusion of either bone marrow or peripheral blood progenitor cells (PBPCs) is a relatively simple process that is performed at the bedside. The bone marrow product is generally used fresh and infused through a central vein over a period of several hours. Autologous products are almost always cryopreserved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/171\">",
"     171",
"    </a>",
"    ]. They are thawed at the bedside and infused rapidly over a period of several minutes.",
"   </p>",
"   <p>",
"    The hematopoietic stem cells engraft within the bone marrow cavity by \"homing\" mechanisms that have not yet been fully elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/172\">",
"     172",
"    </a>",
"    ]. Vascular cell adhesion molecule-1 (VCAM-1), heparan sulfate, and stromal cell-derived factor-1 and its receptor (CXCR4) appear to play roles in this process (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Plerixafor (AMD3100, Mozobil)'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/86,173-175\">",
"     86,173-175",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal toxicity has been observed in the majority of cases. With bone marrow infusions, there is occasional fever, however, most patients tolerate the infusion similar to a blood transfusion. In those instances in which ABO mismatched bone marrow is infused, hemolytic reactions may occur which are treated in standard fashion by administering fluids and diuretics.",
"   </p>",
"   <p>",
"    With the infusion of cryopreserved peripheral blood stem cells, minor toxicities such as fever, cough, nausea, vomiting, flushing, headache and occasional bronchospasm are relatively common and self-limited. Such reactions may be related to the amount of granulocytes or non-mononuclear cells present in the apheresis product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/176,177\">",
"     176,177",
"    </a>",
"    ]. Most reactions disappear rapidly following the completion of the infusion. Significant infusional toxicity such as hypotension, cardiac arrhythmias, and electrolyte disturbances are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infusional toxicities can be reduced by selecting for stem cell populations, such as CD34+ cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/178\">",
"     178",
"    </a>",
"    ]. Major ABO incompatibilities can lead to acute hemolytic transfusion reactions; red blood cells need to be depleted from the infusion in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/49/38682/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Beyond the Basics topics (see",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"     \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapidly expanding field of stem cell biology has resulted in a dramatic improvement in our understanding of the biologic basis of transplantation. With the emergence of peripheral blood progenitor cells (PBPCs) and umbilical cord blood, alternative sources of stem cells are available. The optimal source and composition of the stem cell product continues to be an area of active clinical investigation.",
"     </li>",
"     <li>",
"      In the autologous setting, most transplant groups use PBPCs in the majority of cases. The optimal stem cell dose can be calculated using enumeration of CD34+ cells. As an example, the total number of cells collected as determined by the total nucleated cell count can be multiplied by the percentage of CD34+ cells determined by FACS analysis of the product. In this way, the total number of CD34+ cells can be calculated; this is then divided by the recipient weight to arrive at the number of CD34+",
"      <span class=\"nowrap\">",
"       cells/kg.",
"      </span>",
"      The role of tumor cell purging remains to be directly demonstrated, although a number of techniques that reliably deplete tumor cells from the stem cell products have been developed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hematopoietic stem cell mobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the allogeneic setting, the situation is considerably more complex. The optimal product has yet to be determined with respect to the use of bone marrow versus PBPCs. PBPCs engraft more rapidly than bone marrow, but the increased T cell load may result in higher rates of GVHD, particularly chronic GVHD. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Relative efficacy of PBPC versus bone marrow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative merits of unrelated donor cells versus cord blood versus haploidentical donors remains to be determined, although most centers prefer the use of unrelated donors over the other alternative stem cell sources.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/1\">",
"      Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995; 11:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/2\">",
"      Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/3\">",
"      Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 2005; 56:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/4\">",
"      Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992; 89:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/5\">",
"      Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993; 177:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/6\">",
"      Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/7\">",
"      Nakauchi H. Hematopoietic stem cells: are they CD34-positive or CD34-negative? Nat Med 1998; 4:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/8\">",
"      Negrin RS, Atkinson K, Leemhuis T, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000; 6:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/9\">",
"      M&uuml;ller AM, Kohrt HE, Cha S, et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2012; 18:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/10\">",
"      Bah&ccedil;eci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000; 108:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/11\">",
"      Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/12\">",
"      Zubair AC, Zahrieh D, Daley H, et al. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/13\">",
"      Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003; 102:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/14\">",
"      Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/15\">",
"      Miller JP, Perry EH, Price TH, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/16\">",
"      Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood 1984; 64:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/17\">",
"      Sanders J, Buckner CD, Bensinger WI, et al. Experience with marrow harvesting from donors less than two years of age. Bone Marrow Transplant 1987; 2:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/18\">",
"      Styczynski J, Balduzzi A, Gil L, et al. Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood 2012; 119:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/19\">",
"      McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/20\">",
"      Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/21\">",
"      Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/22\">",
"      Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/23\">",
"      Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013; 121:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/24\">",
"      Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003; 122:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/25\">",
"      Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/26\">",
"      Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/27\">",
"      Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/28\">",
"      Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor \"mobilized\" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/29\">",
"      Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/30\">",
"      de Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001; 41:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/31\">",
"      Kr&ouml;ger N, Renges H, Kr&uuml;ger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/32\">",
"      Van Hennik PB, Breems DA, Kusadasi N, et al. Stroma-supported progenitor production as a prognostic tool for graft failure following autologous stem cell transplantation. Br J Haematol 2000; 111:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/33\">",
"      Jansen EM, Hanks SG, Terry C, et al. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both? Transfusion 2007; 47:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/34\">",
"      Dzik W, Sniecinski I, Fischer J. Toward standardization of CD34+ cell enumeration: an international study. Biomedial Excellence for Safer Transfusion Working Party. Transfusion 1999; 39:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/35\">",
"      Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/36\">",
"      Heuft HG, Dubiel M, Rick O, et al. Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cells in two automated leukapheresis systems. Transfusion 2001; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/37\">",
"      Demirer T, Ilhan O, Ayli M, et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/38\">",
"      Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/39\">",
"      Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/40\">",
"      Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion 2011; 51:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/41\">",
"      Humpe A, Riggert J, Meineke I, et al. A cell-kinetic model of CD34+ cell mobilization and harvest: development of a predictive algorithm for CD34+ cell yield in PBPC collections. Transfusion 2000; 40:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/42\">",
"      Anderlini P, Przepiorka D, Lauppe J, et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/43\">",
"      Tricot G, Morris CL, Siegel E, et al. Peripheral blood stem cell mobilization in elderly (&ge;70 years) versus younger patients: A study of 984 multiple myeloma patients [abstract]. Proc ASCO 2002; 21:264a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/44\">",
"      de La Rubia J, D&iacute;az MA, Verdeguer A, et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion 2001; 41:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/45\">",
"      Cesaro S, Zanazzo AG, Frenos S, et al. A Phase II study on the safety and efficacy of a single dose of pegfilgrastim for mobilization and transplantation of autologous hematopoietic stem cells in pediatric oncohematology patients. Transfusion 2011; 51:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/46\">",
"      de Lavallade H, Ladaique P, Lemari&eacute; C, et al. Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood 2009; 113:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/47\">",
"      Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85:3334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/48\">",
"      Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/49\">",
"      Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/50\">",
"      Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/51\">",
"      Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/52\">",
"      Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98:3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/53\">",
"      Singh AK, Savani BN, Albert PS, Barrett AJ. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2007; 13:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/54\">",
"      Robin M, Kern&egrave;is S, Porcher R, et al. Influence of bone marrow nucleated red blood cell dose on outcome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2008; 140:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/55\">",
"      Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/56\">",
"      Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/57\">",
"      Urbano-Ispizua A, Carreras E, Mar&iacute;n P, et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/58\">",
"      Nakamura R, Bahceci E, Read EJ, et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001; 115:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/59\">",
"      Urbano-Ispizua A, Rozman C, Pimentel P, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/60\">",
"      Mehta J, Mehta J, Frankfurt O, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/61\">",
"      Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/62\">",
"      Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/63\">",
"      Ringd&eacute;n O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/64\">",
"      Duggan PR, Guo D, Luider J, et al. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant 2000; 26:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/65\">",
"      Sumikuma T, Shimazaki C, Inaba T, et al. CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002; 117:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/66\">",
"      Kozuka T, Ikeda K, Teshima T, et al. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion 2002; 42:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/67\">",
"      Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/68\">",
"      Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100:3930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/69\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/70\">",
"      To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118:4530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/71\">",
"      Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/72\">",
"      Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/73\">",
"      Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/74\">",
"      Bolwell BJ, Goormastic M, Yanssens T, et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/75\">",
"      Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/76\">",
"      Sudo Y, Shimazaki C, Ashihara E, et al. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997; 89:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/77\">",
"      Molineux G, McCrea C, Yan XQ, et al. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 1997; 89:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/78\">",
"      Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Blood 1998; 92:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/79\">",
"      Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/80\">",
"      Murray LJ, Luens KM, Estrada MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol 1998; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/81\">",
"      Ballen K. Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant 2007; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/82\">",
"      Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 2008; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/83\">",
"      Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/84\">",
"      Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/85\">",
"      Carlo-Stella C, Di Nicola M, Milani R, et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103:3287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/86\">",
"      Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/87\">",
"      Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/88\">",
"      Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/89\">",
"      Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/90\">",
"      DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/91\">",
"      DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/92\">",
"      Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/93\">",
"      Shepherd RM, Capoccia BJ, Devine SM, et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006; 108:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/94\">",
"      Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/95\">",
"      Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/96\">",
"      Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/97\">",
"      Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/98\">",
"      Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012; 52:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/99\">",
"      Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/100\">",
"      Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/101\">",
"      Ko&ccedil; ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/102\">",
"      Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/103\">",
"      Ameen RM, Alshemmari SH, Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma 2008; 8:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/104\">",
"      Schwella N, Braun A, Ahrens N, et al. Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft. Transfusion 2003; 43:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/105\">",
"      Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/106\">",
"      Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 2007; 47:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/107\">",
"      Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/108\">",
"      Kroschinsky F, H&ouml;lig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/109\">",
"      Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27 Suppl 2:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/110\">",
"      Seshadri T, Al-Farsi K, Stakiw J, et al. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant 2008; 42:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/111\">",
"      Ostronoff M, Ostronoff F, Souto Maior P, et al. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/112\">",
"      Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88:2775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/113\">",
"      Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/114\">",
"      Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/115\">",
"      Gorin NC, Labopin M, Blaise D, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol 2009; 27:3987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/116\">",
"      K&ouml;rbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/117\">",
"      Tj&oslash;nnfjord GE, Steen R, Evensen SA, et al. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/118\">",
"      Anderlini P, K&ouml;rbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/119\">",
"      Remberger M, Ringd&eacute;n O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/120\">",
"      Ringd&eacute;n O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20:4655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/121\">",
"      Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/122\">",
"      Tanimoto TE, Yamaguchi T, Tanaka Y, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/123\">",
"      Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108:4288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/124\">",
"      Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/125\">",
"      Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/126\">",
"      Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/127\">",
"      Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/128\">",
"      Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/129\">",
"      Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/130\">",
"      Mielcarek M, Storer B, Martin PJ, et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012; 119:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/131\">",
"      Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/132\">",
"      Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/133\">",
"      Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22:4872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/134\">",
"      Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/135\">",
"      Lapierre V, Oubouzar N, Aup&eacute;rin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001; 97:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/136\">",
"      Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23:5074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/137\">",
"      Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90:4705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/138\">",
"      Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/139\">",
"      Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/140\">",
"      Brunet S, Urbano-Ispizua A, Ojeda E, et al. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/141\">",
"      Bornh&auml;user M, Platzbecker U, Theuser C, et al. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002; 118:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/142\">",
"      Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005; 128:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/143\">",
"      Cao TM, Shizuru JA, Wong RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005; 105:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/144\">",
"      Larghero J, Rocha V, Porcher R, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol 2007; 138:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/145\">",
"      Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/146\">",
"      Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/147\">",
"      Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/148\">",
"      Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/149\">",
"      Cohen JL, Trenado A, Vasey D, et al. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/150\">",
"      Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/151\">",
"      Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/152\">",
"      L&eacute;onard BM, H&eacute;tu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/153\">",
"      Gorin NC, Labopin M, Reiffers J, et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood 2010; 116:3157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/154\">",
"      Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000; 95:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/155\">",
"      Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986; 315:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/156\">",
"      Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/157\">",
"      Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/158\">",
"      Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 1998; 22:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/159\">",
"      Rowley SD, Jones RJ, Piantadosi S, et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/160\">",
"      Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/161\">",
"      Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/162\">",
"      Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/163\">",
"      Voso MT, Hohaus S, Moos M, Haas R. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma. Blood 1997; 89:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/164\">",
"      Bertolini F, Thomas T, Battaglia M, et al. A new 'two step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplant 1997; 19:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/165\">",
"      Rambaldi A, Borleri G, Dotti G, et al. Innovative two-step negative selection of granulocyte colony-stimulating factor-mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. Blood 1998; 91:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/166\">",
"      Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/167\">",
"      van Heeckeren WJ, Vollweiler J, Fu P, et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/168\">",
"      Kaufman DS, Hanson ET, Lewis RL, et al. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2001; 98:10716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/169\">",
"      Burt RK, Verda L, Kim DA, et al. Embryonic stem cells as an alternate marrow donor source: engraftment without graft-versus-host disease. J Exp Med 2004; 199:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/170\">",
"      Olsen AL, Stachura DL, Weiss MJ. Designer blood: creating hematopoietic lineages from embryonic stem cells. Blood 2006; 107:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/171\">",
"      Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/172\">",
"      Tavassoli M, Hardy CL. Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 1990; 76:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/173\">",
"      Simmons PJ, Masinovsky B, Longenecker BM, et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992; 80:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/174\">",
"      Siczkowski M, Clarke D, Gordon MY. Binding of primitive hematopoietic progenitor cells to marrow stromal cells involves heparan sulfate. Blood 1992; 80:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/175\">",
"      Papayannopoulou T, Priestley GV, Nakamoto B, et al. Molecular pathways in bone marrow homing: dominant role of alpha(4)beta(1) over beta(2)-integrins and selectins. Blood 2001; 98:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/176\">",
"      Calmels B, Lemari&eacute; C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/177\">",
"      Milone G, Pinto V, Mercurio S, et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cell in infused suspention and on patient age (abstract). Blood 2006; 108:402b.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/178\">",
"      Shpall EJ, LeMaistre CF, Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90:4313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/49/38682/abstract/179\">",
"      Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3537 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38682=[""].join("\n");
var outline_f37_49_38682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STEM CELL MODEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Markers on murine stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Markers on human stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SOURCES OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8516461\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63572418\">",
"      Umbilical cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMATOPOIETIC STEM CELL MOBILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Optimal CD34 cell dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inadequate G-CSF response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other mobilizing agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Plerixafor (AMD3100, Mozobil)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mobilization after chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mobilized bone marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RELATIVE EFFICACY OF PBPC VERSUS BONE MARROW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER TRANSPLANT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      T cell dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mobilization of other cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Tumor cell contamination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Tumor cell purging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ex vivo expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Embryonic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INFUSION OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16680?source=related_link\">",
"      Biology and physiology of thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39145?source=related_link\">",
"      Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=related_link\">",
"      Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_49_38683="Prevalence IgE deficiency";
var content_f37_49_38683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of IgE deficiency (&lt;2.5 International units/mL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Study group",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Number of subjects (adults)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Prevalence, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Percentage with selective IgE deficiency&bull;",
"      </td>",
"      <td class=\"subtitle2\">",
"       <p>",
"        Percentage with IgE + other immunoglobulin deficiencies",
"       </p>",
"       <p>",
"        Deficient immunoglobulins, in decreasing order",
"       </p>",
"      </td>",
"      <td class=\"subtitle2\">",
"       Total",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood donors",
"      </td>",
"      <td>",
"       500",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       <p>",
"        1.8",
"       </p>",
"       <p>",
"        IgG4",
"       </p>",
"      </td>",
"      <td>",
"       2.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Allergy and Immunology clinic patients",
"      </td>",
"      <td>",
"       974",
"      </td>",
"      <td>",
"       3.1",
"      </td>",
"      <td>",
"       <p>",
"        5.0",
"       </p>",
"       <p>",
"        IgG4, IgG1, IgG2 &amp; IgG3",
"       </p>",
"      </td>",
"      <td>",
"       8.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rheumatology clinic patients",
"      </td>",
"      <td>",
"       155",
"      </td>",
"      <td>",
"       1.3",
"      </td>",
"      <td>",
"       <p>",
"        8.4",
"       </p>",
"       <p>",
"        IgA2, IgA1, IgG2, IgG4",
"       </p>",
"      </td>",
"      <td>",
"       9.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total",
"      </td>",
"      <td>",
"       1629",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &bull; Normal serum levels of IgG, IgA, IgM, IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J.K. Smith, MD and G. Krishaswamy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38683=[""].join("\n");
var outline_f37_49_38683=null;
var title_f37_49_38684="Causes of stridor other than congenital anomalies";
var content_f37_49_38684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of stridor other than congenital anomalies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Papilloma virus",
"        <br/>",
"        Herpes virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viral",
"       </td>",
"       <td>",
"        Croup (Parainfluenza)",
"        <br/>",
"        RSV",
"        <br/>",
"        Influenza A and B",
"        <br/>",
"        Mycoplasma*",
"       </td>",
"       <td>",
"        Lymphadenopathy caused by CMV and EBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial",
"       </td>",
"       <td>",
"        Epiglottitis",
"        <br/>",
"        Tracheitis",
"        <br/>",
"        Peritonsillar and retropharyngeal abscess",
"        <br/>",
"        Lateral pharyngeal space abscess",
"        <br/>",
"        Diphtheria",
"       </td>",
"       <td>",
"        Lymphadenopathy caused by tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Tumors",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Encephalocele, teratoma, lymphoma, granuloma, fibroma, papilloma, neuroblastoma, hemangioma, rhabdomyosarcoma, cystic hygroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent laryngeal nerve",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Post PDA repair",
"        <br/>",
"        Thyroid surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post extubation",
"       </td>",
"       <td>",
"        Edema",
"       </td>",
"       <td>",
"        Subglottic stenosis",
"        <br/>",
"        Unilateral or bilateral vocal cord paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        Caustic ingestion",
"        <br/>",
"        Inhalation injury",
"        <br/>",
"        Facial trauma or burn",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Allergic",
"       </td>",
"       <td>",
"        Anaphylaxis",
"        <br/>",
"        Hereditary angioneurotic edema",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Neurologic",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        CNS malformation",
"        <br/>",
"        Hypoxic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Metabolic",
"       </td>",
"       <td>",
"        Hypocalcemia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other",
"       </td>",
"       <td>",
"        Airway foreign body",
"        <br/>",
"        Esophageal foreign body",
"        <br/>",
"        Spasmodic croup",
"        <br/>",
"        Exercise",
"        <br/>",
"        Vocal cord dysfunction",
"       </td>",
"       <td>",
"        Gastroesophageal reflux",
"        <br/>",
"        Juvenile idiopathic arthritis&nbsp;(cricoarytenoid arthritis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RSV: respiratory syncytial virus;&nbsp;CMV: cytomegalovirus; EBV: Epstein-Barr virus; PDA: patent ductus arteriosus; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38684=[""].join("\n");
var outline_f37_49_38684=null;
var title_f37_49_38685="Thiazide side effects and dose";
var content_f37_49_38685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Dose-dependence of thiazide-induced side effects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 214px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metabolic complications induced by bendrofluazide in relation to daily dose (multiply by 10 to get equivalent doses of hydrochlorothiazide). Increasing the dose led to progressive hypokalemia and hyperuricemia and a greater likelihood of a mild elevation in the fasting blood glucose (FBG), all without a further reduction in the systemic blood pressure. Each treatment group contained approximately 52 patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Carlsen, JE, Kober, L, Torp-Pedersen, C, Johannsen, P, BMJ 1990; 300:975.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38685=[""].join("\n");
var outline_f37_49_38685=null;
var title_f37_49_38686="Examination of a neck mass";
var content_f37_49_38686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An overall approach to the examination of a neck mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 675px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * When imaging is indicated, CT is the best initial option.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      If the imaging results are nondiagnostic, tissue sampling may be required and FNA is the recommended initial method.",
"      <br>",
"       &Delta; When a specific diagnosis is felt likely, appropriate referral should be made to a practitioner experienced in the management of the suspected lesion.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        When an open procedure is required, referral should be made to a surgeon well-experienced in head and neck surgery, with training in management of diagnostic possibilities including parotid masses, thyroid lesions, vacular lesions, and congenital masses.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38686=[""].join("\n");
var outline_f37_49_38686=null;
var title_f37_49_38687="Conditions associated with malignant hyperthermia";
var content_f37_49_38687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with malignant hyperthermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Conditon",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Mechanism of MH susceptibility",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Inheritance",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       OK to administer?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Volatile agents",
"      </td>",
"      <td class=\"subtitle2\">",
"       Succinylchoine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"6\">",
"       Myopathies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Central core myopathy",
"       <sup>",
"        [1-5]",
"       </sup>",
"      </td>",
"      <td>",
"       Hypotonia in infancy, delayed motor development, proximal lower-limb muscle weakness, associated musculoskeletal abnormalities",
"      </td>",
"      <td>",
"       RYR1 receptor abnormality",
"      </td>",
"      <td>",
"       Autosomal dominant with variable penetrance",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Multicore myopathy",
"       <sup>",
"        [6]",
"       </sup>",
"      </td>",
"      <td>",
"       Similar to central core myopathy",
"      </td>",
"      <td>",
"       SEPN1, RYR1 receptor abnormalities",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       King-Denborough syndrome",
"       <sup>",
"        [7,8]",
"       </sup>",
"      </td>",
"      <td>",
"       Hypotonia at birth, mild proximal muscle weakness, delayed motor development, dysmorphic facial features (ptosis, low-set ears, malar hypoplasia, micrognathia, and a high-arched palate), pectus excavatum, winged scapulae, lumbar lordosis and thoracic scoliosis",
"      </td>",
"      <td>",
"       RYR1",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Native American myopathy",
"       <sup>",
"        [9]",
"       </sup>",
"      </td>",
"      <td>",
"       Affects Lumbee Indians of North Carolina, congenital weakness, arthrogryposis, cleft palate, ptosis, short stature, kyphoscoliosis",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"6\">",
"       Conditions associated with rhabdomyolysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Heat induced rhabdomyolysis",
"       <sup>",
"        [10-12]",
"       </sup>",
"      </td>",
"      <td>",
"       Many anesthesiologists feel that patients with a history of heat stroke and rhabdomyolysis should be considered MH susceptible",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Exercise induced rhabdomyolysis",
"       <sup>",
"        [13-15]",
"       </sup>",
"      </td>",
"      <td>",
"       Similar to heat induced rhabdomyolysis",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Dystrophinopathies",
"       <sup>",
"        [16-27]",
"       </sup>",
"      </td>",
"      <td>",
"       At risk for developing rhabdomyolysis and hyperkalemia following exposure to succinylcholine",
"      </td>",
"      <td>",
"       Dystrophin-glycoprotein complex located within the myocyte, absent dystrophin, extra junctional acetylcholine receptors upregulated to compensate, succinylcholine depolarizes the muscle with exaggerated efflux of calcium from the sarcoplasmic reticulum into the intracellular space",
"      </td>",
"      <td>",
"       <p>",
"        Duchenne's: X-linked recessive",
"       </p>",
"       <p>",
"        Becker's: X-linked recessive",
"       </p>",
"      </td>",
"      <td>",
"       Only if essential, in limited amounts",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Myoadenylate deaminase deficiency",
"       <sup>",
"        [28]",
"       </sup>",
"      </td>",
"      <td>",
"       Muscles cramps, elevated CK levels (baseline and increased after exercise), and occasionally rhabdomyolysis. Single case report with positive contracture test.",
"      </td>",
"      <td>",
"       Defective muscle-specific enzyme impairing energy metabolism of muscle",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       McArdle's disease",
"       <sup>",
"        [29,30]",
"       </sup>",
"      </td>",
"      <td>",
"       Glycogen storage disease type V, muscle cramping, exercise intolerance, rhabdomyolysis. Triggering agents they can exacerbate underlying symptoms.",
"      </td>",
"      <td>",
"       Absence of muscle phosphorylase and therefore the inability to metabolize glycogen",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Carnitine palmitoyl transferase type 2 deficiency",
"       <sup>",
"        [31,32]",
"       </sup>",
"      </td>",
"      <td>",
"       Muscle weakness or cramps and exercise intolerance sometimes associated with rhabdomyolysis. CPT2 deficiency can have perioperative rhabdomyolysis but no definitive link to MH susceptibility has been identified.",
"      </td>",
"      <td>",
"       Fatty-acid oxidation disorder with abnormal breakdown of fats for energy",
"      </td>",
"      <td>",
"       Autosomal recessive",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"      <td>",
"       Try to avoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"6\">",
"       Other conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Osteogenesis imperfecta",
"       <sup>",
"        [33-37]",
"       </sup>",
"      </td>",
"      <td>",
"       \"Brittle bone disease\", diagnoses of MH susceptibility has never been confirmed by contracture testing or genetic mutation analysis",
"      </td>",
"      <td>",
"       No proven MH susceptibility",
"      </td>",
"      <td>",
"       Inherited connective tissue disorder",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Arthrogyroposis",
"       <sup>",
"        [38,39]",
"       </sup>",
"      </td>",
"      <td>",
"       Congenital joint contractures, occurs in a variety of inherited neurogenic or myogenic syndromes, MH has not resulted with any certainty",
"      </td>",
"      <td>",
"       No proven MH susceptibility",
"      </td>",
"      <td>",
"       Variable depending on specific inherited condition",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Myotonia",
"       <sup>",
"        [40]",
"       </sup>",
"      </td>",
"      <td>",
"       Incomplete muscle relaxation with muscle stiffness. Includes myotonic dystrophy, myotonic atrophica, and myotonia congenita.",
"      </td>",
"      <td>",
"       Exposure to triggering agents may induce prolonged muscle rigidity but not considered susceptible",
"      </td>",
"      <td>",
"       Variable depending on specific inherited condition",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Noonan syndrome",
"      </td>",
"      <td>",
"       Phenotypically appears like King-Denborough syndrome with short stature, webbed neck, low-set ears, congenital heart disease, pectus excavatum, varying degrees of developmental delay/mental retardation",
"      </td>",
"      <td>",
"       No proven MH susceptibility",
"      </td>",
"      <td>",
"       Autosomal dominant with variable penetrance",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Neuroleptic malignant syndrome",
"       <sup>",
"        [41-44]",
"       </sup>",
"      </td>",
"      <td>",
"       Similar clinical manifestations as MH but triggered by administration of neuroleptic antipsychotic medications",
"      </td>",
"      <td>",
"       No proven MH susceptibility",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Quane, QA, Healy, JM, Manning, BM, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5:51.",
"     <br>",
"      2. Brandt, A, Schleithoff, L, Jurkat-Rott, K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055.",
"      <br>",
"       3. Sewry, CA, Muller, C, Davis, M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002; 12:930.",
"       <br>",
"        4. Klingler, W, Rueffert, H, Lehmann-Horn, F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109:1167.",
"        <br>",
"         5. Zhang, Y, Chen, HS, Khanna, VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46.",
"         <br>",
"          6. Guis, S, Figarella-Branger, D, Monnier, N, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61:106.",
"          <br>",
"           7. Denborough, M. Malignant hyperthermia. Lancet 1998; 352:1131.",
"           <br>",
"            8. D'Arcy, CE, Bjorksten, A, Yiu, EM, et al. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71:776.",
"            <br>",
"             9. Stamm, DS, Aylsworth, AS, Stajich, JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008; 146A:1832.",
"             <br>",
"              10. Tobin, JR, Jason, DR, Challa, VR, et al. Malignant hyperthermia and apparent heat stroke. JAMA 2001; 286:168.",
"              <br>",
"               11. Denborough, M, Hopkinson, KC, O'Brien, RO, Foster, PS. Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intensive Care 1996; 24:348.",
"               <br>",
"                12. Chelu, MG, Goonasekera, SA, Durham, WJ, et al. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 2006; 20:329.",
"                <br>",
"                 13. Capacchione, JF, Muldoon, SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009; 109:1065.",
"                 <br>",
"                  14. Kochling, A, Wappler, F, Winkler, G, Schulte am, Esch JS. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26:315.",
"                  <br>",
"                   15. Wappler, F, Fiege, M, Steinfath, M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94:95.",
"                   <br>",
"                    16. Bush, A, Dubowitz, V. Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromuscul Disord 1991; 1:201.",
"                    <br>",
"                     17. Tang, TT, Oechler, HW, Siker, D, et al. Anesthesia-induced rhabdomyolysis in infants with unsuspected Duchenne dystrophy. Acta Paediatr 1992; 81:716.",
"                     <br>",
"                      18. Obata, R, Yasumi, Y, Suzuki, A, et al. Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:564.",
"                      <br>",
"                       19. Kerr, TP, Duward, A, Hodgson, SV, et al. Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia. Eur J Pediatr 2001; 160:579.",
"                       <br>",
"                        20. Girshin, M, Mukherjee, J, Clowney, R, et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Paediatr Anaesth 2006; 16:170.",
"                        <br>",
"                         21. Kleopa, KA, Rosenberg, H, Heiman-Patterson, T. Malignant hyperthermia-like episode in Becker muscular dystrophy. Anesthesiology 2000; 93:1535.",
"                         <br>",
"                          22. Hoffman, EP, Brown, RH Jr., Kunkel, LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919.",
"                          <br>",
"                           23. Larach, MG, Rosenberg, H, Gronert, GA, Allen, GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9.",
"                           <br>",
"                            24. Goresky, GV, Cox, RG. Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:525.",
"                            <br>",
"                             25. Boba, A. Fatal postanesthetic complications in two muscular dystrophic patients. J Pediatr Surg 1970; 5:71.",
"                             <br>",
"                              26. Kelfer, HM, Singer, WD, Reynolds, RN. Malignant hyperthermia in a child with Duchenne muscular dystrophy. Pediatrics 1983; 71:118.",
"                              <br>",
"                               27. Gurnaney, H, Brown, A, Litman, RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109:1043.",
"                               <br>",
"                                28. Fricker, RM, Raffelsberger, T, Rauch-Shorny, S, et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 2002; 97:1635.",
"                                <br>",
"                                 29. Lobato, EB, Janelle, GM, Urdaneta, F, Malias, MA. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91:303.",
"                                 <br>",
"                                  30. Bollig, G, Mohr, S, Raeder, J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 2005; 49:1077.",
"                                  <br>",
"                                   31. Katsuya, H, Misumi, M, Ohtani, Y, Miike, T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology 1988; 68:945.",
"                                   <br>",
"                                    32. Hogan, KJ, Vladutiu, GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg 2009; 109:1070.",
"                                    <br>",
"                                     33. Ryan, CA, Al-Ghamdi, AS, Gayle, M, Finer, NN. Osteogenesis imperfecta and hyperthermia. Anesth Analg 1989; 68:811.",
"                                     <br>",
"                                      34. Kill, C, Leonhardt, A, Wulf, H. Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta. Paediatr Anaesth 2003; 13:823.",
"                                      <br>",
"                                       35. Rampton, AJ, Kelly, DA, Shanahan, EC, Ingram, GS. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta. Br J Anaesth 1984; 56:1443.",
"                                       <br>",
"                                        36. Porsborg, P, Astrup, G, Bendixen, D, et al. Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship?. Anaesthesia 1996; 51:863.",
"                                        <br>",
"                                         37. Martin, S, Tobias, JD. Perioperative care of the child with arthrogryposis. Paediatr Anaesth 2006; 16:31.",
"                                         <br>",
"                                          38. Baines, DB, Douglas, ID, Overton, JH. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia?. Anaesth Intensive Care 1986; 14:370.",
"                                          <br>",
"                                           39. Hopkins, PM, Ellis, FR, Halsall, PJ. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 1991; 46:374.",
"                                           <br>",
"                                            40. Parness, J, Bandschapp, O, Girard, T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg 2009; 109:1054.",
"                                            <br>",
"                                             41. Smego, RA Jr, Durack, DT. The neuroleptic malignant syndrome. Arch Intern Med 1982; 142:1183.",
"                                             <br>",
"                                              42. Caroff, SN, Rosenberg, H, Fletcher, JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.",
"                                              <br>",
"                                               43. Ward, A, Chaffman, MO, Sorkin, EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32:130.",
"                                               <br>",
"                                                44. Bello, N, Adnet, P, Saulnier, F, et al. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome]. Ann Fr Anesth Reanim 1994; 13:663.",
"                                               </br>",
"                                              </br>",
"                                             </br>",
"                                            </br>",
"                                           </br>",
"                                          </br>",
"                                         </br>",
"                                        </br>",
"                                       </br>",
"                                      </br>",
"                                     </br>",
"                                    </br>",
"                                   </br>",
"                                  </br>",
"                                 </br>",
"                                </br>",
"                               </br>",
"                              </br>",
"                             </br>",
"                            </br>",
"                           </br>",
"                          </br>",
"                         </br>",
"                        </br>",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_49_38687=[""].join("\n");
var outline_f37_49_38687=null;
